Inhibition	O
of	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
activation	O
attenuates	O
apoptosis	O
resistance	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

Death-inducing	B-protein
ligands	I-protein
(	O
DILs	B-protein
)	O
such	O
as	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
)	O
or	O
the	O
cytotoxic	O
drug	O
doxorubicin	O
have	O
been	O
shown	O
to	O
activate	O
a	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NFkappaB	B-protein
)	O
-dependent	O
program	O
that	O
may	O
rescue	O
cells	O
from	O
apoptosis	O
induction	O
.	O

We	O
demonstrate	O
here	O
that	O
TRAIL	B-protein
(	O
TNF-related	B-protein
apoptosis-inducing	I-protein
ligand	I-protein
)	O
,	O
a	O
recently	O
identified	O
DIL	B-protein
,	O
also	O
activates	O
NFkappaB	B-protein
in	O
lymphoid	O
cell	O
lines	O
in	O
a	O
kinetic	O
similar	O
to	O
TNFalpha	B-protein
.	O

NFkappaB	B-protein
activity	O
is	O
independent	O
from	O
FADD	B-protein
,	O
caspases	B-protein
,	O
and	O
apoptosis	O
induction	O
.	O

To	O
study	O
the	O
influence	O
of	O
NFkappaB	B-protein
activity	O
on	O
apoptosis	O
mediated	O
by	O
TRAIL	B-protein
,	O
CD95	O
,	O
TNFalpha	B-protein
,	O
or	O
doxorubicin	O
,	O
NFkappaB	B-protein
activation	O
was	O
inhibited	O
using	O
the	O
proteasome	B-protein
inhibitor	O
N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal	O
or	O
transient	O
overexpression	O
of	O
mutant	B-protein
IkappaBalpha	I-protein
.	O

Sensitivity	O
for	O
induction	O
of	O
apoptosis	O
was	O
markedly	O
increased	O
by	O
these	O
treatments	O
in	O
apoptosis	O
sensitive	O
cell	B-cell_line
lines	I-cell_line
.	O

Moreover	O
,	O
both	O
in	O
cell	O
lines	O
and	O
in	O
primary	O
leukemia	O
cells	O
that	O
are	O
resistant	O
towards	O
induction	O
of	O
apoptosis	O
by	O
DILs	B-protein
and	O
doxorubicin	O
,	O
antagonization	O
of	O
NFkappaB	B-protein
activity	O
partially	O
restored	O
apoptosis	O
sensitivity	O
.	O

These	O
data	O
suggest	O
that	O
inhibition	O
of	O
NFkappaB	B-protein
activation	O
may	O
provide	O
a	O
molecular	O
approach	O
to	O
increase	O
apoptosis	O
sensitivity	O
in	O
anticancer	O
treatment	O
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Inhibition	NULL
of	NULL
Nuclear	NULL
Factor	NULL
«	NULL
B	NULL
Activation	NULL
Attenuates	NULL
Apoptosis	NULL
Resistance	NULL
in	NULL
Lymphoid	NULL
Cells	NULL
By	NULL
|	NULL
.	NULL

Jeremias	NULL
,	NULL
C.	NULL
Kupatt	NULL
,	NULL
B.	NULL
Baumann	NULL
,	NULL
I.	NULL
Herr	NULL
,	NULL
T.	NULL
Wirth	NULL
,	NULL
and	NULL
K.M	NULL
.	NULL

Debatin	NULL
Death-inducing	NULL
ligands	NULL
(	NULL
DILs	NULL
)	NULL
such	NULL
as	NULL
tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
(	NULL
TNFa	NULL
)	NULL
or	NULL
the	NULL
cytotoxic	NULL
drug	NULL
doxorubicin	NULL
have	NULL
been	NULL
show	NULL
n	NULL
to	NULL
activate	NULL
a	NULL
nuclear	NULL
factor	NULL
«	NULL
B	NULL
program	NULL
that	NULL
may	NULL
rescue	NULL
cells	NULL
from	NULL
apoptosis	NULL
induction	NULL
.	NULL

We	NULL
demonstrate	NULL
here	NULL
that	NULL
TRAIL	NULL
(	NULL
TNF-related	NULL
apoptosis-inducing	NULL
li-gand	NULL
)	NULL
,	NULL
a	NULL
recently	NULL
identified	NULL
DIL	NULL
,	NULL
also	NULL
activates	NULL
NFkB	NULL
in	NULL
lymphoid	NULL
cell	NULL
lines	NULL
in	NULL
a	NULL
kinetic	NULL
similar	NULL
to	NULL
TNFa	NULL
.	NULL

NFB	NULL
activity	NULL
is	NULL
independent	NULL
from	NULL
FADD	NULL
,	NULL
caspases	NULL
,	NULL
and	NULL
apoptosis	NULL
induction	NULL
.	NULL

To	NULL
study	NULL
the	NULL
influence	NULL
of	NULL
NFkB	NULL
activity	NULL
on	NULL
apoptosis	NULL
mediated	NULL
by	NULL
TRAIL	NULL
,	NULL
CD95	NULL
,	NULL
TNFa	NULL
,	NULL
or	NULL
doxorubicin	NULL
,	NULL
NFkB	NULL
activation	NULL
was	NULL
inhibited	NULL
using	NULL
the	NULL
proteasome	NULL
inhibitor	NULL
ESISTANCE	NULL
OF	NULL
TUMOR	NULL
cells	NULL
towards	NULL
induction	NULL
of	NULL
apoptosis	NULL
is	NULL
a	NULL
main	NULL
reason	NULL
for	NULL
failure	NULL
of	NULL
anticancer	NULL
treatment	NULL
.	NULL

!	NULL
``	NULL

Recent	NULL
studies	NULL
suggest	NULL
that	NULL
Nuclear	NULL
factor	NULL
«	NULL
kB	NULL
(	NULL
NFB	NULL
)	NULL
may	NULL
mediate	NULL
a	NULL
survival	NULL
pathway	NULL
in	NULL
many	NULL
cells	NULL
.	NULL
``	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
suggest	NULL
that	NULL
inhibition	NULL
of	NULL
NFB	NULL
activation	NULL
may	NULL
decrease	NULL
apoptosis	NULL
resistance	NULL
for	NULL
death-inducing	NULL
ligands	NULL
(	NULL
DILs	NULL
)	NULL
and	NULL
cytostatic	NULL
drugs	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

NFB	NULL
is	NULL
a	NULL
DNA	NULL
binding	NULL
protein	NULL
that	NULL
augments	NULL
transcription	NULL
of	NULL
various	NULL
genes	NULL
involved	NULL
in	NULL
cell	NULL
proliferation	NULL
,	NULL
such	NULL
as	NULL
growth	NULL
factors	NULL
.	NULL
``	NULL

NFB	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
for	NULL
cell	NULL
development	NULL
,	NULL
*	NULL
survival	NULL
,	NULL
and	NULL
oncogenesis	NULL
,	NULL
``	NULL
eg	NULL
,	NULL
in	NULL
the	NULL
immune	NULL
system	NULL
,	NULL
``	NULL
and	NULL
mediates	NULL
its	NULL
function	NULL
through	NULL
homodimers	NULL
or	NULL
heterodimers	NULL
formed	NULL
by	NULL
family	NULL
members	NULL
(	NULL
RelA/p65	NULL
,	NULL
RelB	NULL
,	NULL
c-rel	NULL
,	NULL
NFKkB1/	NULL
p50	NULL
,	NULL
and	NULL
NFKkB2/p52	NULL
)	NULL
.©	NULL
In	NULL
quiescent	NULL
cells	NULL
,	NULL
cytosolic	NULL
NFB	NULL
is	NULL
bound	NULL
to	NULL
inhibitory	NULL
IxB-proteins	NULL
.	NULL

``	NULL
>	NULL
``	NULL
Upon	NULL
activation	NULL
,	NULL
IxB	NULL
becomes	NULL
phosphorylated	NULL
,	NULL
ubiquitinated	NULL
,	NULL
and	NULL
subsequentially	NULL
degraded	NULL
by	NULL
proteasomes	NULL
,	NULL
``	NULL
enabling	NULL
nuclear	NULL
translocation	NULL
and	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
activated	NULL
NFB	NULL
.	NULL
``	NULL

A	NULL
variety	NULL
of	NULL
different	NULL
stimuli	NULL
activate	NULL
NFB	NULL
,	NULL
such	NULL
as	NULL
oxida-tive	NULL
stress	NULL
,	NULL
cytokines	NULL
,	NULL
and	NULL
apoptosis-inducing	NULL
stimuli	NULL
including	NULL
drugs	NULL
used	NULL
in	NULL
anticancer	NULL
treatment	NULL
.	NULL

'*	NULL
'	NULL
``	NULL
Most	NULL
importantly	NULL
,	NULL
direct	NULL
triggering	NULL
of	NULL
death	NULL
receptors	NULL
,	NULL
eg	NULL
,	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
(	NULL
TNFa	NULL
)	NULL
,	NULL
may	NULL
activate	NULL
a	NULL
NFB	NULL
dependent	NULL
pathway	NULL
that	NULL
antagonizes	NULL
apoptosis	NULL
.	NULL

Induction	NULL
of	NULL
apoptosis	NULL
by	NULL
TNFa	NULL
involves	NULL
signaling	NULL
through	NULL
adapter	NULL
molecules	NULL
such	NULL
as	NULL
FADD	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
intracellular	NULL
death	NULL
domain	NULL
of	NULL
the	NULL
respective	NULL
receptor	NULL
via	NULL
TRADD	NULL
to	NULL
activate	NULL
downstream	NULL
caspases	NULL
and	NULL
apoptosis	NULL
effec-tors	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
activation	NULL
of	NULL
NFB	NULL
seems	NULL
to	NULL
be	NULL
the	NULL
consequence	NULL
of	NULL
a	NULL
pathway	NULL
that	NULL
is	NULL
independent	NULL
from	NULL
FADD-mediated	NULL
From	NULL
the	NULL
Division	NULL
of	NULL
Molecular	NULL
Oncology	NULL
,	NULL
Deutsches	NULL
Krebsfor-schungszentrum	NULL
,	NULL
Heidelberg	NULL
,	NULL
Germany	NULL
;	NULL
the	NULL
Department	NULL
of	NULL
Physiology	NULL
,	NULL
University	NULL
Munich	NULL
,	NULL
Germany	NULL
;	NULL
the	NULL
Institut	NULL
filr	NULL
Medizinische	NULL
Strahlen-kunde	NULL
und	NULL
Zellforschung	NULL
,	NULL
University	NULL
Wiirzburg	NULL
,	NULL
Germany	NULL
;	NULL
and	NULL
the	NULL
University	NULL
Childrens	NULL
'	NULL
Hospital	NULL
,	NULL
Ulm	NULL
,	NULL
Germany	NULL
.	NULL

Submitted	NULL
November	NULL
25	NULL
,	NULL
1997	NULL
;	NULL
accepted	NULL
February	NULL
7	NULL
,	NULL
1998	NULL
.	NULL

Supported	NULL
by	NULL
Deutsche	NULL
Forschungsgemeinschaft	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Prof	NULL
Dr	NULL
Klaus-Michael	NULL
Debatin	NULL
,	NULL
University	NULL
Childrens	NULL
'	NULL
Hospital	NULL
,	NULL
Prittwitzstr	NULL
.	NULL

43	NULL
,	NULL
D-89075	NULL
Ulm	NULL
,	NULL
Germany	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
adver-tisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-4971/98/9112-0017	NULL
$	NULL
3.00/0	NULL
4624	NULL
N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal	NULL
or	NULL
transient	NULL
overexpression	NULL
of	NULL
mutant	NULL
IxBa	NULL
«	NULL
.	NULL

Sensitivity	NULL
for	NULL
induction	NULL
of	NULL
apoptosis	NULL
was	NULL
markedly	NULL
increased	NULL
by	NULL
these	NULL
treatments	NULL
in	NULL
apoptosis	NULL
sensitive	NULL
cell	NULL
lines	NULL
.	NULL

Moreover	NULL
,	NULL
both	NULL
in	NULL
cell	NULL
lines	NULL
and	NULL
in	NULL
primary	NULL
leukemia	NULL
cells	NULL
that	NULL
are	NULL
resistant	NULL
towards	NULL
induction	NULL
of	NULL
apoptosis	NULL
by	NULL
DILs	NULL
and	NULL
doxorubicin	NULL
,	NULL
antagonization	NULL
of	NULL
NFB	NULL
activity	NULL
partially	NULL
restored	NULL
apoptosis	NULL
sensitivity	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
inhibition	NULL
of	NULL
NFB	NULL
activation	NULL
may	NULL
provide	NULL
a	NULL
molecular	NULL
approach	NULL
to	NULL
increase	NULL
apoptosis	NULL
sensitivity	NULL
in	NULL
anticancer	NULL
treatment	NULL
.	NULL

©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

death	NULL
signaling	NULL
and	NULL
involves	NULL
different	NULL
adapter	NULL
molecules	NULL
such	NULL
as	NULL
TRAF/NIK	NULL
.	NULL

!	NULL

*	NULL
TNFa	NULL
activates	NULL
NFB	NULL
in	NULL
a	NULL
broad	NULL
spectrum	NULL
of	NULL
cells	NULL
and	NULL
activation	NULL
of	NULL
NFB	NULL
was	NULL
shown	NULL
to	NULL
modify	NULL
induction	NULL
of	NULL
apoptosis	NULL
.	NULL
``	NULL

''	NULL
``	NULL
``	NULL
Thus	NULL
,	NULL
in	NULL
RelA	NULL
-/-	NULL
cells	NULL
'	NULL
``	NULL
or	NULL
cells	NULL
overexpressing	NULL
IxB	NULL
,	NULL
``	NULL
``	NULL
induction	NULL
of	NULL
apoptosis	NULL
by	NULL
TNFa	NULL
is	NULL
markedly	NULL
enhanced	NULL
.	NULL

Apart	NULL
from	NULL
TNFa	NULL
,	NULL
two	NULL
additional	NULL
DILs	NULL
are	NULL
characterized	NULL
so	NULL
far	NULL
,	NULL
all	NULL
members	NULL
of	NULL
the	NULL
TNF	NULL
superfamily	NULL
:	NULL
CD95-ligand	NULL
(	NULL
CD95-L	NULL
)	NULL
and	NULL
TRAIL	NULL
(	NULL
TNF-related	NULL
apoptosis-inducing	NULL
ligand	NULL
)	NULL
.	NULL

CD95-L	NULL
activates	NULL
NFB	NULL
in	NULL
a	NULL
cell-type-specific	NULL
manner	NULL
and	NULL
independently	NULL
from	NULL
its	NULL
cytotoxic	NULL
function	NULL
.	NULL

'**	NULL
'	NULL
Recently	NULL
,	NULL
a	NULL
new	NULL
DIL	NULL
was	NULL
found	NULL
,	NULL
TRAIL	NULL
,	NULL
**	NULL
>	NULL
**	NULL
that	NULL
mediates	NULL
apoptosis	NULL
by	NULL
its	NULL
receptors	NULL
DR4/TRAIL-R1/TRICK1*®	NULL
``	NULL
and	NULL
DRS/TRAIL-R2	NULL
TRICK2	NULL
,	NULL
``	NULL
*	NULL
>	NULL
'	NULL
eg	NULL
,	NULL
in	NULL
leukemic	NULL
cells	NULL
.	NULL
``	NULL

We	NULL
report	NULL
here	NULL
that	NULL
TRAIL	NULL
activates	NULL
NFB	NULL
in	NULL
lymphoid	NULL
cell	NULL
lines	NULL
.	NULL

Inhibition	NULL
of	NULL
NFB	NULL
activation	NULL
strongly	NULL
increases	NULL
apoptosis	NULL
sensitivity	NULL
in	NULL
some	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
found	NULL
that	NULL
inhibition	NULL
of	NULL
NFB	NULL
activation	NULL
enables	NULL
induction	NULL
of	NULL
apoptosis	NULL
by	NULL
several	NULL
DILs	NULL
as	NULL
well	NULL
as	NULL
cytostatic	NULL
drugs	NULL
in	NULL
cells	NULL
that	NULL
are	NULL
cross-resistant	NULL
for	NULL
apoptosis	NULL
induction	NULL
by	NULL
DILs	NULL
and	NULL
drugs	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
lines	NULL
and	NULL
culture	NULL
.	NULL

All	NULL
cell	NULL
lines	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
medium	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
Conco	NULL
,	NULL
Wiesbaden	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
100	NULL
U/mL	NULL
penicilin	NULL
,	NULL
100	NULL
ug/mL	NULL
streptomycin	NULL
,	NULL
and	NULL
10	NULL
mmol/L	NULL
HEPES	NULL
(	NULL
all	NULL
GIBCO	NULL
,	NULL
Life	NULL
Technologies	NULL
,	NULL
Paisley	NULL
,	NULL
Scotland	NULL
)	NULL
.	NULL

For	NULL
all	NULL
assays	NULL
cells	NULL
were	NULL
seeded	NULL
at	NULL
a	NULL
density	NULL
of	NULL
10°	NULL
cells/mL	NULL
.	NULL

The	NULL
following	NULL
cell	NULL
lines	NULL
were	NULL
used	NULL
:	NULL
CEM	NULL
and	NULL
Jurkat	NULL
,	NULL
acute	NULL
T-cell	NULL
leukemia	NULL
;	NULL
BJAB	NULL
,	NULL
Burkitt	NULL
lymphoma	NULL
;	NULL
BOE	NULL
and	NULL
PD31	NULL
,	NULL
premature	NULL
B-cell	NULL
leukemia	NULL
;	NULL
CEM-R	NULL
and	NULL
Jurkat-R	NULL
,	NULL
derivative	NULL
cell	NULL
lines	NULL
resistant	NULL
to	NULL
doxorubicin-induced	NULL
apoptosis	NULL
and	NULL
cross-resistant	NULL
against	NULL
DIL-induced	NULL
apoptosis	NULL
.	NULL

CEM-R	NULL
cells	NULL
were	NULL
generated	NULL
by	NULL
culturing	NULL
parental	NULL
CEM	NULL
cells	NULL
in	NULL
increasing	NULL
doses	NULL
of	NULL
doxorubicin	NULL
for	NULL
several	NULL
months	NULL
and	NULL
Jurakt-R	NULL
cells	NULL
were	NULL
cultivated	NULL
in	NULL
anti-APO-1	NULL
,	NULL
respectively	NULL
.	NULL

Stimulation	NULL
of	NULL
cells	NULL
.	NULL

-	NULL
Doxorubicin	NULL
(	NULL
Sigma	NULL
,	NULL
Deisenhofen	NULL
,	NULL
Germany	NULL
)	NULL
was	NULL
dissolved	NULL
in	NULL
water	NULL
,	NULL
supplemented	NULL
with	NULL
ethanol	NULL
to	NULL
a	NULL
96	NULL
%	NULL
ethanol	NULL
stock	NULL
solution	NULL
(	NULL
1	NULL
mg/mL	NULL
)	NULL
,	NULL
and	NULL
stored	NULL
in	NULL
aliquots	NULL
at	NULL
-80°C	NULL
.	NULL

TNFa	NULL
.	NULL

was	NULL
purchased	NULL
from	NULL
Boehringer	NULL
(	NULL
Mannheim	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal	NULL
(	NULL
LLnL	NULL
;	NULL
Sigma	NULL
)	NULL
was	NULL
dissolved	NULL
in	NULL
dimethylsulf-oxide	NULL
(	NULL
DMSO	NULL
)	NULL
to	NULL
a	NULL
25	NULL
mmol/L	NULL
stock	NULL
solution	NULL
.	NULL

N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl-ketone	NULL
(	NULL
zVAD	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
Enzyme	NULL
System	NULL
Products	NULL
(	NULL
Dublin	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
dissolved	NULL
in	NULL
DMSO	NULL
to	NULL
a	NULL
50	NULL
mmol/L	NULL
stock	NULL
solution	NULL
.	NULL

Phorbol	NULL
myristic	NULL
acetate	NULL
(	NULL
PMA	NULL
;	NULL
Sigma	NULL
)	NULL
was	NULL
dissolved	NULL
in	NULL
DMSO	NULL
to	NULL
a	NULL
100	NULL
pg/mL	NULL
stock	NULL
solution	NULL
.	NULL

Ionomycin	NULL
(	NULL
Sigma	NULL
)	NULL
was	NULL
dissolved	NULL
in	NULL
96	NULL
%	NULL
ethanol	NULL
to	NULL
a	NULL
5	NULL
mg/mL	NULL
stock	NULL
solution	NULL
.	NULL

TNFa	NULL
,	NULL
LLnL	NULL
,	NULL
zVAD	NULL
,	NULL
PMA	NULL
,	NULL
and	NULL
Ionomycin	NULL
were	NULL
stored	NULL
in	NULL
aliquots	NULL
at	NULL
-20°C	NULL
.	NULL

TRAIL	NULL
was	NULL
produced	NULL
as	NULL
described	NULL
.	NULL
``	NULL

Briefly	NULL
,	NULL
TRAIL	NULL
cDNA	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
Blood	NULL
,	NULL
Vol	NULL
91	NULL
,	NULL
No	NULL
12	NULL
(	NULL
June	NULL
15	NULL
)	NULL
,	NULL
1998	NULL
:	NULL
pp	NULL
4624-4631	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

INHIBITION	NULL
OF	NULL
NFkB	NULL
ATTENUATES	NULL
APOPTOSIS	NULL
RESISTANCE	NULL
vector	NULL
pPIC3	NULL
and	NULL
transfected	NULL
into	NULL
Pichia	NULL
Pastoris	NULL
strain	NULL
GS115	NULL
(	NULL
Invitrogen	NULL
,	NULL
NY	NULL
Leek	NULL
,	NULL
The	NULL
Netherlands	NULL
)	NULL
.	NULL

Protein	NULL
production	NULL
was	NULL
induced	NULL
by	NULL
culturing	NULL
yeast	NULL
in	NULL
2.5	NULL
%	NULL
methanol	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
and	NULL
TRAIL	NULL
purified	NULL
by	NULL
nickel-histidine	NULL
interaction	NULL
(	NULL
Qiagen	NULL
,	NULL
Hamburg	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

LLnL	NULL
and	NULL
zVAD	NULL
were	NULL
preincubated	NULL
in	NULL
stimulation	NULL
assays	NULL
for	NULL
1	NULL
hour	NULL
.	NULL

Electrophoresis	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

-	NULL
Cells	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
lysed	NULL
in	NULL
600	NULL
mmol/L	NULL
KCI	NULL
,	NULL
20	NULL
mmol/L	NULL
HEPES	NULL
,	NULL
200	NULL
umol/L	NULL
EDTA	NULL
(	NULL
all	NULL
Merck	NULL
,	NULL
Darmstadt	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
1	NULL
mmol/L	NULL
Phenylmethylsulfony	NULL
]	NULL
fluoride	NULL
(	NULL
PMSF	NULL
)	NULL
,	NULL
2	NULL
ug/mL	NULL
Aprotinin	NULL
,	NULL
and	NULL
2	NULL
ug/mL	NULL
Leupeptin	NULL
(	NULL
all	NULL
Sigma	NULL
)	NULL
for	NULL
45	NULL
minutes	NULL
on	NULL
ice	NULL
in	NULL
5	NULL
packed	NULL
cell	NULL
volumes	NULL
and	NULL
centrifuged	NULL
at	NULL
12,000g	NULL
for	NULL
5	NULL
minutes	NULL
.	NULL

Five	NULL
micrograms	NULL
of	NULL
supernatant	NULL
was	NULL
incubated	NULL
with	NULL
poly	NULL
dIdC	NULL
(	NULL
1	NULL
ug	NULL
;	NULL
Pharmacia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
in	NULL
binding	NULL
buffer	NULL
(	NULL
10	NULL
mmol/L	NULL
Tris-HCI	NULL
,	NULL
pH	NULL
7.45	NULL
,	NULL
50	NULL
mmol/L	NULL
NaCl	NULL
,	NULL
0.5	NULL
mmol/L	NULL
EDTA	NULL
,	NULL
1	NULL
mmol/L	NULL
dithiothreitol	NULL
[	NULL
DTT	NULL
]	NULL
,	NULL
50	NULL
umol/L	NULL
PMSF	NULL
,	NULL
2	NULL
vol	NULL
%	NULL
glycerol	NULL
,	NULL
2	NULL
%	NULL
Ficoll	NULL
400	NULL
)	NULL
for	NULL
20	NULL
minutes	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Lysats	NULL
were	NULL
exposed	NULL
for	NULL
15	NULL
minutes	NULL
at	NULL
room	NULL
temperature	NULL
to	NULL
double-stranded	NULL
oligonucleotides	NULL
for	NULL
the	NULL
consensus	NULL
binding	NULL
sites	NULL
of	NULL
NFkB	NULL
(	NULL
5	NULL
AGT	NULL
TGA	NULL
GGG	NULL
GAC	NULL
TTT	NULL
CCC	NULL
AGG	NULL
C	NULL
3	NULL
'	NULL
)	NULL
that	NULL
had	NULL
been	NULL
labaled	NULL
with	NULL
[	NULL
°°P	NULL
]	NULL
-ATP	NULL
(	NULL
Amersham	NULL
,	NULL
Braunschweig	NULL
,	NULL
Germany	NULL
)	NULL
by	NULL
polynucleotide	NULL
kinase	NULL
(	NULL
Boehringer	NULL
)	NULL
.	NULL

Protein-oligo	NULL
mixtures	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
nondenaturing	NULL
6	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
0.5	NULL
%	NULL
TBE	NULL
.	NULL

Gels	NULL
were	NULL
dried	NULL
and	NULL
exposed	NULL
to	NULL
an	NULL
x-ray	NULL
film	NULL
.	NULL

For	NULL
specific	NULL
competition	NULL
,	NULL
proteins	NULL
were	NULL
preincubated	NULL
with	NULL
unlabeled	NULL
NFkB	NULL
binding	NULL
oligonucleotide	NULL
in	NULL
100-fold	NULL
excess	NULL
;	NULL
for	NULL
supershift	NULL
,	NULL
preincubation	NULL
was	NULL
performed	NULL
using	NULL
2	NULL
uL	NULL
anti-p50	NULL
,	NULL
5	NULL
uL	NULL
anti-p65	NULL
,	NULL
or	NULL
1.5	NULL
uL	NULL
anti-c-rel	NULL
antibody	NULL
(	NULL
all	NULL
Santa	NULL
Cruz	NULL
,	NULL
Heidelberg	NULL
,	NULL
Germany	NULL
)	NULL
for	NULL
1	NULL
hour	NULL
on	NULL
ice	NULL
.	NULL

Western	NULL
blotting	NULL
.	NULL

-	NULL
Cells	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
and	NULL
lysed	NULL
for	NULL
5	NULL
minutes	NULL
on	NULL
ice	NULL
in	NULL
10	NULL
packed	NULL
cell	NULL
volumes	NULL
using	NULL
30	NULL
mmol/L	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
150	NULL
mmol/L	NULL
NaCl	NULL
,	NULL
1	NULL
mmol/L	NULL
EDTA	NULL
,	NULL
0,5	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
0.5	NULL
%	NULL
Na-Desoxycholate	NULL
,	NULL
1	NULL
mmol/L	NULL
DTT	NULL
,	NULL
1	NULL
mmol/L	NULL
PMSF	NULL
,	NULL
2	NULL
ug/mL	NULL
Aprotinin	NULL
,	NULL
and	NULL
2	NULL
ug/mL	NULL
Leupeptin	NULL
.	NULL

Cell	NULL
debris	NULL
were	NULL
removed	NULL
,	NULL
and	NULL
15	NULL
ug	NULL
of	NULL
proteins	NULL
was	NULL
run	NULL
on	NULL
a	NULL
12	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
SDS-PAGE	NULL
)	NULL
and	NULL
blotted	NULL
onto	NULL
a	NULL
nylon	NULL
membrane	NULL
.	NULL

Filter	NULL
was	NULL
hybridized	NULL
with	NULL
anti-IkBa	NULL
antibody	NULL
and	NULL
subsequentially	NULL
with	NULL
antirabbit	NULL
antibody	NULL
coupled	NULL
to	NULL
horseradish	NULL
peroxidase	NULL
(	NULL
both	NULL
Santa	NULL
Cruz	NULL
)	NULL
.	NULL

For	NULL
detection	NULL
,	NULL
an	NULL
Enhanced	NULL
Chemilumiscent	NULL
System	NULL
(	NULL
Amersham	NULL
)	NULL
was	NULL
used	NULL
.	NULL

Equal	NULL
protein	NULL
loading	NULL
was	NULL
proven	NULL
by	NULL
subsequential	NULL
Ponceau	NULL
red	NULL
staining	NULL
of	NULL
the	NULL
filter	NULL
.	NULL

Measurement	NULL
of	NULL
apoptosis	NULL
.	NULL

Apoptosis	NULL
was	NULL
measured	NULL
by	NULL
forward	NULL
side	NULL
scatter	NULL
analysis	NULL
in	NULL
FACScan	NULL
flow	NULL
cytometer	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
equipped	NULL
with	NULL
the	NULL
Cell	NULL
Quest	NULL
2.0	NULL
Software	NULL
.	NULL

Specific	NULL
apoptosis	NULL
was	NULL
calculated	NULL
as	NULL
described	NULL
.	NULL

``	NULL
?	NULL

Transfections	NULL
.	NULL

Cells	NULL
(	NULL
3	NULL
X	NULL
10	NULL
``	NULL
)	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
PBS	NULL
and	NULL
resuspended	NULL
in	NULL
200	NULL
uL	NULL
PBS	NULL
.	NULL

Twenty	NULL
micrograms	NULL
of	NULL
specific	NULL
plasmid	NULL
DNA	NULL
(	NULL
mock	NULL
or	NULL
IxBa	NULL
)	NULL
and	NULL
2	NULL
ug	NULL
plasmid	NULL
DNA	NULL
containing	NULL
pEGFP	NULL
DNA	NULL
for	NULL
transfection	NULL
control	NULL
(	NULL
Clontech	NULL
,	NULL
Heidelberg	NULL
,	NULL
Germany	NULL
)	NULL
was	NULL
added	NULL
.	NULL

The	NULL
IxBa	NULL
mutant	NULL
construct	NULL
contains	NULL
alanines	NULL
in	NULL
positions	NULL
32	NULL
and	NULL
36	NULL
instead	NULL
of	NULL
serines	NULL
to	NULL
disable	NULL
phosphorylation	NULL
and	NULL
degradation	NULL
of	NULL
the	NULL
protein	NULL
.	NULL
``	NULL

Electroporation	NULL
was	NULL
performed	NULL
(	NULL
240	NULL
V	NULL
,	NULL
975	NULL
uF	NULL
)	NULL
and	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
10	NULL
mL	NULL
fresh	NULL
medium	NULL
.	NULL

After	NULL
48	NULL
hours	NULL
,	NULL
living	NULL
cells	NULL
were	NULL
separated	NULL
by	NULL
Ficoll	NULL
gradient	NULL
and	NULL
subsequentially	NULL
stimulated	NULL
for	NULL
another	NULL
12	NULL
hours	NULL
.	NULL

Forward	NULL
side	NULL
scatter	NULL
FACScan	NULL
analysis	NULL
was	NULL
performed	NULL
gating	NULL
on	NULL
green	NULL
fluorescent	NULL
protein	NULL
(	NULL
GFP	NULL
)	NULL
-positive	NULL
cells	NULL
.	NULL

Measurement	NULL
of	NULL
apoptosis	NULL
in	NULL
primary	NULL
leukemic	NULL
cells	NULL
.	NULL

-	NULL
At	NULL
the	NULL
time	NULL
of	NULL
diagnosis	NULL
of	NULL
acute	NULL
leukemia	NULL
,	NULL
mononuclear	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
6	NULL
patients	NULL
'	NULL
bone	NULL
marrow	NULL
cells	NULL
using	NULL
Ficoll	NULL
gradient	NULL
centrifugation	NULL
.	NULL

Staining	NULL
of	NULL
membrane	NULL
antigens	NULL
showed	NULL
the	NULL
percentage	NULL
of	NULL
blast	NULL
cells	NULL
to	NULL
be	NULL
greater	NULL
than	NULL
90	NULL
%	NULL
in	NULL
all	NULL
patients	NULL
.	NULL

Cells	NULL
were	NULL
seeded	NULL
at	NULL
a	NULL
density	NULL
of	NULL
10°	NULL
cells/mL	NULL
and	NULL
incubated	NULL
at	NULL
37°C	NULL
,	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
in	NULL
humidity	NULL
.	NULL

Spontaneous	NULL
apoptosis	NULL
was	NULL
measured	NULL
continuously	NULL
using	NULL
Trypan	NULL
blue	NULL
staining	NULL
.	NULL

As	NULL
soon	NULL
as	NULL
35	NULL
%	NULL
of	NULL
cells	NULL
or	NULL
more	NULL
stained	NULL
positive	NULL
(	NULL
6	NULL
to	NULL
12	NULL
hours	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
the	NULL
experiment	NULL
was	NULL
stopped	NULL
and	NULL
apoptosis	NULL
was	NULL
measured	NULL
in	NULL
a	NULL
FACScan	NULL
using	NULL
forward	NULL
side	NULL
scatter	NULL
analysis	NULL
.	NULL

4625	NULL
RESULTS	NULL
Activation	NULL
of	NULL
NFB	NULL
by	NULL
TRAIL	NULL
.	NULL

We	NULL
used	NULL
electromobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
to	NULL
investigate	NULL
whether	NULL
TRAIL	NULL
is	NULL
able	NULL
to	NULL
activate	NULL
NFB	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
1A	NULL
,	NULL
enhanced	NULL
NFB	NULL
binding	NULL
activity	NULL
was	NULL
found	NULL
as	NULL
early	NULL
as	NULL
10	NULL
minutes	NULL
after	NULL
stimulation	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
TRAIL	NULL
(	NULL
0.3	NULL
ug/mL	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
NFB	NULL
was	NULL
further	NULL
enhanced	NULL
after	NULL
30	NULL
minutes	NULL
and	NULL
was	NULL
A	NULL
so	NULL
min	NULL
P/	NULL
TR	NULL
TR	NULL
30	NULL
30	NULL
30	NULL
10	NULL
30	NULL
|__	NULL
|	NULL
___	NULL
|L	NULL
__	NULL
|__|	NULL
NFB	NULL
wfe	NULL
of=	NULL
[	NULL
g..	NULL

I	NULL
Fig	NULL
1	NULL
.	NULL

Activation	NULL
of	NULL
NFB	NULL
by	NULL
TRAIL	NULL
(	NULL
A	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
PMA	NULL
(	NULL
50	NULL
ng/mL	NULL
)	NULL
lonomycin	NULL
(	NULL
2	NULL
g/mL	NULL
)	NULL
(	NULL
P/1	NULL
)	NULL
or	NULL
TRAIL	NULL
(	NULL
0.3	NULL
g/mL	NULL
)	NULL
(	NULL
TB	NULL
)	NULL
for	NULL
the	NULL
time	NULL
periods	NULL
indicated	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
,	NULL
cellular	NULL
proteins	NULL
were	NULL
isolated	NULL
,	NULL
and	NULL
EMSA	NULL
was	NULL
performed	NULL
.	NULL

sc	NULL
,	NULL
specific	NULL
competition	NULL
with	NULL
unlabeled	NULL
oligonucleotide	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
TRAIL	NULL
(	NULL
0.3	NULL
pg/mL	NULL
)	NULL
for	NULL
30	NULL
minutes	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
LLnL	NULL
(	NULL
6.25	NULL
pmol/L	NULL
,	NULL
1	NULL
hour	NULL
of	NULL
pretreatment	NULL
)	NULL
.	NULL

Fifteen	NULL
micrograms	NULL
of	NULL
protein	NULL
extract	NULL
was	NULL
run	NULL
on	NULL
a	NULL
12	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

Proteins	NULL
were	NULL
transferred	NULL
onto	NULL
a	NULL
nylon	NULL
filter	NULL
that	NULL
was	NULL
subsequentially	NULL
hybridized	NULL
with	NULL
an	NULL
anti-l	NULL
«	NULL
Be	NULL
antibody	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
CEM	NULL
cells	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

4626	NULL
comparable	NULL
with	NULL
stimulation	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
PMA/	NULL
Tonomycin	NULL
(	NULL
Fig	NULL
1A	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
NFB	NULL
by	NULL
TRAIL	NULL
was	NULL
also	NULL
observed	NULL
in	NULL
CEM	NULL
cells	NULL
and	NULL
in	NULL
the	NULL
murine	NULL
pre-B-cell	NULL
line	NULL
PD31	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

TNFa	NULL
also	NULL
activated	NULL
NFB	NULL
in	NULL
most	NULL
cell	NULL
lines	NULL
tested	NULL
,	NULL
whereas	NULL
CD95-triggering	NULL
did	NULL
not	NULL
consistently	NULL
induce	NULL
NFB	NULL
activation	NULL
``	NULL
(	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

TRAIL-induced	NULL
NFB	NULL
binding	NULL
activity	NULL
was	NULL
mediated	NULL
by	NULL
a	NULL
complex	NULL
of	NULL
dimers	NULL
containing	NULL
p50	NULL
and	NULL
p65	NULL
proteins	NULL
as	NULL
demonstrated	NULL
by	NULL
supershift	NULL
experiments	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

NFKB	NULL
activation	NULL
was	NULL
accompanied	NULL
by	NULL
degradation	NULL
of	NULL
its	NULL
cytosolic	NULL
inhibitor	NULL
IxBa	NULL
,	NULL
which	NULL
could	NULL
be	NULL
blocked	NULL
by	NULL
the	NULL
proteasome	NULL
inhibitor	NULL
LLnL	NULL
,	NULL
as	NULL
detected	NULL
in	NULL
Western	NULL
blot	NULL
(	NULL
Fig	NULL
1B	NULL
)	NULL
.	NULL

Independence	NULL
of	NULL
TRAIL-mediated	NULL
NFB	NULL
activation	NULL
from	NULL
FADD	NULL
and	NULL
caspases	NULL
.	NULL

-	NULL
Because	NULL
TRAIL	NULL
mediates	NULL
two	NULL
effects	NULL
,	NULL
namely	NULL
induction	NULL
of	NULL
apoptosis	NULL
and	NULL
activation	NULL
of	NULL
NFkB	NULL
,	NULL
we	NULL
examined	NULL
whether	NULL
both	NULL
signals	NULL
use	NULL
the	NULL
same	NULL
intracellular	NULL
signaling	NULL
pathway	NULL
.	NULL

After	NULL
stimulation	NULL
with	NULL
TRAIL	NULL
,	NULL
BJAB	NULL
cells	NULL
stably	NULL
overexpressing	NULL
a	NULL
dominant	NULL
negative	NULL
FADD	NULL
mutant	NULL
protein	NULL
displayed	NULL
similar	NULL
NFkB	NULL
activation	NULL
compared	NULL
with	NULL
mock-transfected	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
TRAIL-mediated	NULL
NFkB	NULL
activation	NULL
is	NULL
indepedent	NULL
from	NULL
FADD	NULL
signaling	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
TRAIL-induced	NULL
activation	NULL
of	NULL
NFB	NULL
involves	NULL
known	NULL
downstream	NULL
effector	NULL
molecules	NULL
for	NULL
apoptosis	NULL
mediated	NULL
by	NULL
TRAIL	NULL
,	NULL
we	NULL
examined	NULL
NFB	NULL
activation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
inhibition	NULL
of	NULL
caspase	NULL
activity	NULL
.	NULL

ZVAD	NULL
,	NULL
a	NULL
broad	NULL
spectrum	NULL
inhibitor	NULL
of	NULL
caspases	NULL
that	NULL
is	NULL
known	NULL
to	NULL
block	NULL
TRAIL-induced	NULL
apoptosis	NULL
,	NULL
``	NULL
had	NULL
no	NULL
significant	NULL
influence	NULL
on	NULL
activation	NULL
of	NULL
NFB	NULL
by	NULL
TRAIL	NULL
(	NULL
Fig	NULL
2	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
both	NULL
intracellular	NULL
signaling	NULL
pathways	NULL
are	NULL
at	NULL
least	NULL
partially	NULL
independent	NULL
.	NULL

Increase	NULL
in	NULL
apoptosis	NULL
sensitivity	NULL
of	NULL
CEM	NULL
cells	NULL
by	NULL
inhibition	NULL
of	NULL
NFkB	NULL
activation	NULL
.	NULL

-	NULL
Because	NULL
the	NULL
two	NULL
signals	NULL
mediated	NULL
by	NULL
TRAIL	NULL
use	NULL
different	NULL
intracellular	NULL
signaling	NULL
transmission	NULL
,	NULL
we	NULL
further	NULL
examined	NULL
the	NULL
influence	NULL
of	NULL
one	NULL
signal	NULL
on	NULL
the	NULL
other	NULL
,	NULL
here	NULL
of	NULL
coactivated	NULL
NFB	NULL
activity	NULL
on	NULL
DIL	NULL
and	NULL
drug-induced	NULL
apoptosis	NULL
.	NULL

We	NULL
used	NULL
parental	NULL
CEM	NULL
cells	NULL
(	NULL
Fig	NULL
3	NULL
)	NULL
and	NULL
CEM-R	NULL
cells	NULL
,	NULL
a	NULL
derivative	NULL
cell	NULL
line	NULL
resistant	NULL
to	NULL
doxorubicin-induced	NULL
apoptosis	NULL
and	NULL
cross-resistant	NULL
for	NULL
DILs	NULL
such	NULL
as	NULL
TRAIL	NULL
(	NULL
Fig	NULL
4	NULL
)	NULL
.	NULL

Both	NULL
cell	NULL
lines	NULL
are	NULL
resistant	NULL
towards	NULL
TNFa-induced	NULL
apoptosis	NULL
in	NULL
the	NULL
TRAIL	NULL
co	NULL
P	NULL
/I	NULL
SC	NULL
=	NULL
LLnL	NULL
_	NULL
zVAD	NULL
Fig	NULL
2	NULL
.	NULL

Independence	NULL
of	NULL
TRAIL-mediated	NULL
NFkB	NULL
activation	NULL
from	NULL
caspases	NULL
.	NULL

CEM	NULL
cells	NULL
were	NULL
preincubated	NULL
with	NULL
LLnL	NULL
(	NULL
2.5	NULL
pmol/L	NULL
)	NULL
or	NULL
zVAD	NULL
(	NULL
50	NULL
pmol/L	NULL
)	NULL
for	NULL
1	NULL
hour	NULL
.	NULL

TRAIL	NULL
(	NULL
0.3	NULL
pg/mL	NULL
)	NULL
or	NULL
PMA	NULL
(	NULL
50	NULL
ng/	NULL
mL	NULL
)	NULL
/	NULL
lonomycin	NULL
(	NULL
2	NULL
mg/mL	NULL
)	NULL
(	NULL
P/l	NULL
)	NULL
was	NULL
added	NULL
for	NULL
another	NULL
30	NULL
minutes	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
and	NULL
EMSA	NULL
was	NULL
performed	NULL
.	NULL

sc	NULL
,	NULL
specific	NULL
competition	NULL
with	NULL
unlabeled	NULL
oligo	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
using	NULL
Jurkat	NULL
cells	NULL
.	NULL

JEREMIAS	NULL
ET	NULL
AL	NULL
absence	NULL
of	NULL
cycloheximide	NULL
.	NULL

Treatment	NULL
of	NULL
CEM	NULL
cells	NULL
with	NULL
LLL	NULL
in	NULL
concentrations	NULL
that	NULL
block	NULL
NFB	NULL
activation	NULL
(	NULL
compare	NULL
Fig	NULL
2	NULL
)	NULL
strongly	NULL
enhanced	NULL
apoptosis	NULL
induced	NULL
by	NULL
low	NULL
doses	NULL
of	NULL
TRAIL	NULL
(	NULL
Fig	NULL
3A	NULL
)	NULL
.	NULL

This	NULL
increase	NULL
in	NULL
apoptosis	NULL
sensitivity	NULL
was	NULL
additionally	NULL
found	NULL
in	NULL
the	NULL
acute	NULL
T-cell	NULL
leukemia	NULL
line	NULL
Jurkat	NULL
(	NULL
Fig	NULL
3B	NULL
)	NULL
,	NULL
the	NULL
Burkitt	NULL
lymphoma	NULL
line	NULL
BJAB	NULL
(	NULL
Fig	NULL
3C	NULL
)	NULL
,	NULL
and	NULL
in	NULL
response	NULL
to	NULL
anti-APO-1	NULL
,	NULL
TNFa	NULL
,	NULL
and	NULL
doxorubicin	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
BJAB	NULL
cells	NULL
stably	NULL
overexpressing	NULL
a	NULL
dominant	NULL
negative	NULL
mutant	NULL
FADD	NULL
protein	NULL
that	NULL
are	NULL
resistant	NULL
towards	NULL
TRAIL-induced	NULL
apoptosis**~	NULL
``	NULL
°	NULL
did	NULL
not	NULL
acquire	NULL
sensitivity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
LLnL	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
FADD-mediated	NULL
signaling	NULL
pathway	NULL
is	NULL
indepedent	NULL
from	NULL
NFkB	NULL
(	NULL
Fig	NULL
3C	NULL
)	NULL
.	NULL

To	NULL
see	NULL
more	NULL
specifically	NULL
whether	NULL
the	NULL
underlying	NULL
mechanism	NULL
of	NULL
LLnL	NULL
function	NULL
is	NULL
dependent	NULL
on	NULL
NFKB	NULL
blockade	NULL
,	NULL
we	NULL
used	NULL
transient	NULL
overexpression	NULL
of	NULL
a	NULL
nondegradable	NULL
IxBa	NULL
mutant	NULL
protein	NULL
.	NULL

Cotransfection	NULL
with	NULL
the	NULL
gene	NULL
for	NULL
the	NULL
GFP	NULL
marker	NULL
protein	NULL
enabled	NULL
separate	NULL
forward	NULL
side	NULL
scatter	NULL
FACScan	NULL
analysis	NULL
of	NULL
transfected	NULL
cells	NULL
.	NULL

Using	NULL
this	NULL
treatment	NULL
,	NULL
apoptosis	NULL
induced	NULL
by	NULL
all	NULL
three	NULL
DILs	NULL
was	NULL
markedly	NULL
enhanced	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
mutant	NULL
IxBa	NULL
in	NULL
comparison	NULL
to	NULL
mock-transfected	NULL
cells	NULL
(	NULL
Fig	NULL
3D	NULL
and	NULL
E	NULL
)	NULL
.	NULL

Abrogation	NULL
of	NULL
apoptosis	NULL
resistance	NULL
in	NULL
CEM-R	NULL
cells	NULL
by	NULL
inhibition	NULL
of	NULL
NFkB	NULL
activation	NULL
.	NULL

While	NULL
inhibition	NULL
of	NULL
NFkB	NULL
activation	NULL
augments	NULL
induction	NULL
of	NULL
apoptosis	NULL
,	NULL
we	NULL
asked	NULL
whether	NULL
it	NULL
would	NULL
further	NULL
affect	NULL
apoptosis	NULL
resistance	NULL
.	NULL

CEM-R	NULL
cells	NULL
are	NULL
resistant	NULL
towards	NULL
apoptosis	NULL
mediated	NULL
by	NULL
doxorubicin	NULL
and	NULL
certain	NULL
DILs	NULL
.	NULL

In	NULL
both	NULL
cell	NULL
lines	NULL
,	NULL
apoptosis-sensitive	NULL
CEM	NULL
cells	NULL
and	NULL
apoptosis-resistant	NULL
CEM-R	NULL
cells	NULL
,	NULL
TRAIL	NULL
mediates	NULL
activation	NULL
of	NULL
NFB	NULL
comparable	NULL
to	NULL
activation	NULL
by	NULL
PMA/Ionomycin	NULL
(	NULL
Fig	NULL
4A	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
basal	NULL
NFB	NULL
activity	NULL
of	NULL
unstimulated	NULL
cells	NULL
was	NULL
not	NULL
consistently	NULL
different	NULL
between	NULL
CEM	NULL
and	NULL
CEM-R	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Using	NULL
LLnL	NULL
,	NULL
CEM-R	NULL
cells	NULL
were	NULL
clearly	NULL
sensitized	NULL
towards	NULL
induction	NULL
of	NULL
apoptosis	NULL
by	NULL
high	NULL
doses	NULL
of	NULL
TRAIL	NULL
(	NULL
Fig	NULL
4B	NULL
)	NULL
,	NULL
anti-APO-1	NULL
,	NULL
and	NULL
TNFa	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Most	NULL
importantly	NULL
,	NULL
LLnL	NULL
also	NULL
mediated	NULL
sensitivity	NULL
for	NULL
induction	NULL
of	NULL
apoptosis	NULL
by	NULL
doxorubicin	NULL
in	NULL
these	NULL
otherwise	NULL
completely	NULL
resistant	NULL
cells	NULL
(	NULL
Fig	NULL
4C	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
LLnL	NULL
restored	NULL
DIL	NULL
and	NULL
doxorubicin	NULL
sensitivity	NULL
in	NULL
the	NULL
apoptosis-resistant	NULL
cell	NULL
lines	NULL
Jurkat-R	NULL
and	NULL
BOE	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
transient	NULL
overexpression	NULL
of	NULL
mutant	NULL
IxBa	NULL
strongly	NULL
increased	NULL
apoptosis	NULL
sensitivity	NULL
,	NULL
predominantly	NULL
for	NULL
TRAIL	NULL
and	NULL
TNFa	NULL
(	NULL
Fig	NULL
4D	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
inhibition	NULL
of	NULL
NFKB	NULL
activation	NULL
enables	NULL
induction	NULL
of	NULL
apoptosis	NULL
in	NULL
otherwise	NULL
resistant	NULL
cell	NULL
lines	NULL
.	NULL

Attenuation	NULL
of	NULL
apoptosis	NULL
resistance	NULL
in	NULL
primary	NULL
leukemia	NULL
cells	NULL
by	NULL
inhibition	NULL
of	NULL
NFB	NULL
activation	NULL
.	NULL

-	NULL
To	NULL
see	NULL
whether	NULL
our	NULL
findings	NULL
obtained	NULL
with	NULL
cell	NULL
lines	NULL
would	NULL
be	NULL
relevant	NULL
for	NULL
primary	NULL
tumor	NULL
cells	NULL
,	NULL
we	NULL
studied	NULL
bone	NULL
marrow	NULL
cells	NULL
from	NULL
6	NULL
patients	NULL
with	NULL
acute	NULL
leukemias	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
increased	NULL
spontaneous	NULL
apoptosis	NULL
,	NULL
short-term	NULL
incubations	NULL
were	NULL
performed	NULL
.	NULL

In	NULL
each	NULL
case	NULL
,	NULL
the	NULL
experiment	NULL
was	NULL
terminated	NULL
when	NULL
the	NULL
percentage	NULL
of	NULL
spontaneous	NULL
apoptosis	NULL
exceeded	NULL
35	NULL
%	NULL
.	NULL

Leukemic	NULL
cell	NULL
from	NULL
all	NULL
patients	NULL
displayed	NULL
almost	NULL
complete	NULL
resistance	NULL
towards	NULL
induction	NULL
of	NULL
apoptosis	NULL
by	NULL
DILs	NULL
ex	NULL
vivo	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
5A	NULL
,	NULL
inhibition	NULL
of	NULL
NFxB	NULL
activation	NULL
by	NULL
LLnL	NULL
led	NULL
to	NULL
a	NULL
strong	NULL
increase	NULL
in	NULL
sensitivity	NULL
for	NULL
TRAIL	NULL
induced	NULL
apoptosis	NULL
in	NULL
5	NULL
of	NULL
6	NULL
patient	NULL
samples	NULL
.	NULL

In	NULL
2	NULL
patients	NULL
,	NULL
we	NULL
further	NULL
tested	NULL
apoptosis	NULL
induction	NULL
by	NULL
additional	NULL
DILs	NULL
.	NULL

LLnL	NULL
markedly	NULL
increased	NULL
apoptosis	NULL
sensitivity	NULL
triggered	NULL
by	NULL
€D95	NULL
or	NULL
TNF-receptor	NULL
I	NULL
in	NULL
both	NULL
primary	NULL
common	NULL
ALL	NULL
cells	NULL
(	NULL
Fig	NULL
5B	NULL
)	NULL
and	NULL
primary	NULL
AML	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

INHIBITION	NULL
OF	NULL
NFkB	NULL
ATTENUATES	NULL
APOPTOSIS	NULL
RESISTANCE	NULL
4627	NULL
Aso	NULL
-	NULL
B	NULL
100	NULL
e	NULL
=	NULL
on	NULL
1	NULL
T	NULL
25	NULL
+	NULL
specific	NULL
apoptosis	NULL
(	NULL
%	NULL
)	NULL
specific	NULL
apoptosis	NULL
(	NULL
%	NULL
)	NULL
s	NULL
U	NULL
o	NULL
O	NULL
specific	NULL
apoptosis	NULL
(	NULL
%	NULL
)	NULL
N	NULL
Un	NULL
'	NULL
|	NULL
___	NULL
--	NULL
-t	NULL
--	NULL
-0	NULL
0	NULL
0	NULL
0	NULL
0,03	NULL
0,1	NULL
0	NULL
0,01	NULL
0,03	NULL
0,1	NULL
0	NULL
0,01	NULL
0,03	NULL
TRAIL	NULL
(	NULL
ug/ml	NULL
)	NULL
TRAIL	NULL
(	NULL
ug/ml	NULL
)	NULL
TRAIL	NULL
(	NULL
ug/ml	NULL
)	NULL
D	NULL
so	NULL
-	NULL
E	NULL
30	NULL
+	NULL
<	NULL
g	NULL
.	NULL

F	NULL
8	NULL
$	NULL
G	NULL
8	NULL
15	NULL
+	NULL
&	NULL
15	NULL
€	NULL
a	NULL
o	NULL
g	NULL
``	NULL
3	NULL
``	NULL
s	NULL
0	NULL
$	NULL
#	NULL
t	NULL
0	NULL
TRAIL	NULL
anti-APO-1	NULL
TNF	NULL
0	NULL
4	NULL
mock	NULL
|+|	NULL
_	NULL
+	NULL
+	NULL
0	NULL
0,01	NULL
90:03	NULL
|	NULL
tkBo	NULL
:	NULL
+	NULL
+	NULL
+	NULL
TRAIL	NULL
(	NULL
ug/ml	NULL
)	NULL
Fig	NULL
3	NULL
.	NULL

Increase	NULL
in	NULL
apoptosis	NULL
sensitivity	NULL
of	NULL
CEM	NULL
cells	NULL
by	NULL
inhibition	NULL
of	NULL
NFB	NULL
activation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
CEM	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
TRAIL	NULL
in	NULL
the	NULL
concentrations	NULL
indicated	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
@	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
0	NULL
)	NULL
of	NULL
LLnL	NULL
(	NULL
2.5	NULL
mol/L	NULL
,	NULL
1	NULL
hour	NULL
of	NULL
preincubation	NULL
)	NULL
for	NULL
24	NULL
hours	NULL
.	NULL

Apoptosis	NULL
was	NULL
measured	NULL
using	NULL
forward	NULL
side	NULL
scatter	NULL
analysis	NULL
in	NULL
FACScan	NULL
.	NULL

Data	NULL
are	NULL
the	NULL
mean	NULL
of	NULL
duplicates	NULL
with	NULL
a	NULL
standard	NULL
deviation	NULL
less	NULL
than	NULL
10	NULL
%	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
five	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
as	NULL
in	NULL
(	NULL
A	NULL
)	NULL
using	NULL
LLnL	NULL
at	NULL
6.25	NULL
wmol/	NULL
L.	NULL
Data	NULL
are	NULL
the	NULL
mean	NULL
of	NULL
duplicates	NULL
with	NULL
a	NULL
standard	NULL
deviation	NULL
less	NULL
than	NULL
10	NULL
%	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
tw	NULL
o	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
C	NULL
)	NULL
BJAB	NULL
cells	NULL
,	NULL
either	NULL
mock-transfected	NULL
(	NULL
C	NULL
,	NULL
@	NULL
)	NULL
or	NULL
overexpressing	NULL
a	NULL
dominant	NULL
negative	NULL
FADD	NULL
mutant	NULL
protein	NULL
(	NULL
0	NULL
,	NULL
MI	NULL
)	NULL
were	NULL
treated	NULL
as	NULL
in	NULL
(	NULL
A	NULL
)	NULL
using	NULL
LLnL	NULL
at	NULL
25	NULL
pmol/L	NULL
.	NULL

Data	NULL
are	NULL
the	NULL
mean	NULL
of	NULL
duplicates	NULL
with	NULL
a	NULL
standard	NULL
deviation	NULL
less	NULL
than	NULL
10	NULL
%	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
D	NULL
)	NULL
CEM	NULL
cells	NULL
(	NULL
3	NULL
x	NULL
10	NULL
``	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
20	NULL
g	NULL
of	NULL
empty	NULL
vector	NULL
pPRB	NULL
or	NULL
pPRB	NULL
containing	NULL
the	NULL
cDNA	NULL
for	NULL
mutant	NULL
IxBa	NULL
«	NULL
(	NULL
serines	NULL
on	NULL
position	NULL
32	NULL
and	NULL
36	NULL
were	NULL
replaced	NULL
by	NULL
alanines	NULL
)	NULL
and	NULL
cotransfected	NULL
with	NULL
2	NULL
g	NULL
of	NULL
pEGFP	NULL
.	NULL

After	NULL
48	NULL
hours	NULL
,	NULL
living	NULL
cells	NULL
were	NULL
separated	NULL
by	NULL
Ficoll	NULL
gradient	NULL
and	NULL
stimulated	NULL
with	NULL
different	NULL
concentrations	NULL
of	NULL
TRAIL	NULL
for	NULL
another	NULL
24	NULL
hours	NULL
.	NULL

Apoptosis	NULL
was	NULL
measured	NULL
by	NULL
forward	NULL
side	NULL
scatter	NULL
analysis	NULL
in	NULL
FACScan	NULL
cytometer	NULL
gating	NULL
on	NULL
GFP-positive	NULL
cells	NULL
.	NULL

Specific	NULL
apoptosis	NULL
was	NULL
calculated	NULL
using	NULL
as	NULL
control	NULL
unstimulated	NULL
,	NULL
GFP-positive	NULL
cells	NULL
transfected	NULL
with	NULL
mock	NULL
or	NULL
IkB	NULL
«	NULL
,	NULL
respectively	NULL
.	NULL

Data	NULL
are	NULL
the	NULL
mean	NULL
of	NULL
triplicates	NULL
with	NULL
a	NULL
standard	NULL
deviation	NULL
less	NULL
than	NULL
10	NULL
%	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
E	NULL
)	NULL
CEM	NULL
cells	NULL
were	NULL
transfected	NULL
as	NULL
in	NULL
(	NULL
D	NULL
)	NULL
and	NULL
subsequentially	NULL
stimulated	NULL
with	NULL
TRAIL	NULL
(	NULL
0.03	NULL
g/	NULL
mL	NULL
)	NULL
,	NULL
anti-APO-1	NULL
(	NULL
0.3	NULL
g/mL	NULL
)	NULL
,	NULL
or	NULL
TNFa	NULL
(	NULL
0.3	NULL
ug/	NULL
mL	NULL
)	NULL
for	NULL
another	NULL
24	NULL
hours	NULL
.	NULL

Specific	NULL
apoptosis	NULL
was	NULL
calculated	NULL
as	NULL
in	NULL
(	NULL
D	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
the	NULL
mean	NULL
of	NULL
triplicates	NULL
with	NULL
a	NULL
standard	NULL
deviation	NULL
less	NULL
than	NULL
10	NULL
%	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
using	NULL
Jurkat	NULL
cells	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

4628	NULL
CEM	NULL
JEREMIAS	NULL
ET	NULL
AL	NULL
CEM-R	NULL
co	NULL
P/A	NULL
-	NULL
TRAIL	NULL
co	NULL
P/I	NULL
-	NULL
TRAIL	NULL
brag	NULL
pmu®	NULL
|	NULL
|~	NULL
B	NULL
59	NULL
1	NULL
C	NULL
5	NULL
3	NULL
D4	NULL
1	NULL
£3	NULL
2	NULL
4	NULL
2	NULL
$	NULL
$	NULL
$	NULL
20	NULL
|	NULL
a.	NULL
ta	NULL
o	NULL
9	NULL
25	NULL
|	NULL
9	NULL
17,5	NULL
+	NULL
£	NULL
hg	NULL
a	NULL
0	NULL
0	NULL
g	NULL
E	NULL
§	NULL
I6	NULL
'	NULL
6	NULL
0	NULL
0	NULL
2	NULL
a	NULL
0	NULL
TRAIL	NULL
anti-APO-1	NULL
TNFa	NULL
:	NULL
0	NULL
0	NULL
mock	NULL
]	NULL
+	NULL
+	NULL
+	NULL
IkBo	NULL
.	NULL

+	NULL
+	NULL
+	NULL
0	NULL
0,1	NULL
_	NULL
0,3	NULL
1	NULL
0	NULL
_	NULL
01	NULL
-	NULL
0,3	NULL
1	NULL
TRAIL	NULL
(	NULL
pg/m0	NULL
doxorubicin	NULL
(	NULL
pg/ml	NULL
)	NULL
Fig	NULL
4	NULL
.	NULL

Abrogation	NULL
of	NULL
apoptosis	NULL
resistance	NULL
in	NULL
CEM-R	NULL
cells	NULL
by	NULL
inhibition	NULL
of	NULL
NFB	NULL
activation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
CEM	NULL
and	NULL
CEM-R	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
TRAIL	NULL
(	NULL
0.3	NULL
pg/mL	NULL
)	NULL
or	NULL
PM	NULL
A	NULL
(	NULL
50	NULL
ng/	NULL
mL	NULL
)	NULL
/	NULL
lonomycin	NULL
(	NULL
2	NULL
g/	NULL
mL	NULL
)	NULL
(	NULL
P/1	NULL
)	NULL
for	NULL
30	NULL
minutes	NULL
and	NULL
EMSA	NULL
was	NULL
performed	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
B	NULL
)	NULL
CEM-R	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
TRAIL	NULL
at	NULL
the	NULL
concentrations	NULL
indicated	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
@	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
0	NULL
)	NULL
of	NULL
LLnL	NULL
(	NULL
1.5	NULL
pmol/L	NULL
,	NULL
1	NULL
hour	NULL
of	NULL
preincubation	NULL
)	NULL
.	NULL

After	NULL
12	NULL
hours	NULL
,	NULL
apoptosis	NULL
was	NULL
measured	NULL
by	NULL
forward	NULL
side	NULL
scatter	NULL
analysis	NULL
and	NULL
specific	NULL
apoptosis	NULL
was	NULL
calculated	NULL
.	NULL

Data	NULL
are	NULL
the	NULL
mean	NULL
of	NULL
duplicates	NULL
with	NULL
a	NULL
standard	NULL
deviation	NULL
less	NULL
than	NULL
10	NULL
%	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
C	NULL
)	NULL
CEM-R	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
doxorubicin	NULL
in	NULL
concentrations	NULL
indicated	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
@	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
C	NULL
)	NULL
of	NULL
LLnL	NULL
(	NULL
1.5	NULL
pmol/L	NULL
,	NULL
1	NULL
hour	NULL
of	NULL
preincubation	NULL
)	NULL
for	NULL
48	NULL
hours	NULL
.	NULL

Apoptosis	NULL
was	NULL
measured	NULL
as	NULL
in	NULL
(	NULL
A	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
the	NULL
mean	NULL
of	NULL
duplicates	NULL
with	NULL
a	NULL
standard	NULL
deviation	NULL
less	NULL
than	NULL
10	NULL
%	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
D	NULL
)	NULL
CEM-R	NULL
cells	NULL
(	NULL
5	NULL
x	NULL
10	NULL
``	NULL
)	NULL
were	NULL
transfected	NULL
as	NULL
in	NULL
(	NULL
Fig	NULL
3D	NULL
)	NULL
.	NULL

Stimulation	NULL
was	NULL
performed	NULL
using	NULL
TRAIL	NULL
(	NULL
1	NULL
pg/mL	NULL
)	NULL
,	NULL
anti-APO-1	NULL
(	NULL
0.01	NULL
pg/mL	NULL
)	NULL
,	NULL
or	NULL
TNFa	NULL
(	NULL
0.3	NULL
pg/	NULL
mL	NULL
)	NULL
and	NULL
apoptosis	NULL
was	NULL
measured	NULL
after	NULL
12	NULL
hours	NULL
of	NULL
incubation	NULL
.	NULL

Data	NULL
are	NULL
the	NULL
mean	NULL
of	NULL
duplicates	NULL
with	NULL
a	NULL
standard	NULL
deviation	NULL
less	NULL
than	NULL
10	NULL
%	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
tw	NULL
o	NULL
independent	NULL
experiments	NULL
.	NULL

that	NULL
the	NULL
influence	NULL
of	NULL
inhibition	NULL
of	NULL
NFB	NULL
activity	NULL
on	NULL
apoptosis	NULL
resistance	NULL
might	NULL
be	NULL
clinically	NULL
relevant	NULL
.	NULL

DISCUSSION	NULL
In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
inhibition	NULL
of	NULL
NFB	NULL
activation	NULL
augments	NULL
DIL	NULL
and	NULL
drug-induced	NULL
apoptosis	NULL
and	NULL
significantly	NULL
decreases	NULL
apoptosis	NULL
resistance	NULL
.	NULL

DILs	NULL
such	NULL
as	NULL
CD95-L	NULL
and	NULL
TNFa	NULL
are	NULL
known	NULL
to	NULL
activate	NULL
NFB	NULL
independently	NULL
of	NULL
their	NULL
cytotoxic	NULL
function	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
TRAIL	NULL
also	NULL
activates	NULL
NFkB	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

Activation	NULL
of	NULL
NFB	NULL
by	NULL
TRAIL	NULL
is	NULL
independent	NULL
from	NULL
FADD	NULL
,	NULL
caspases	NULL
,	NULL
and	NULL
induction	NULL
of	NULL
apoptosis	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
two	NULL
intracellular	NULL
signaling	NULL
pathways	NULL
initiated	NULL
by	NULL
TRAIL	NULL
separate	NULL
at	NULL
an	NULL
early	NULL
stage	NULL
close	NULL
to	NULL
the	NULL
receptors	NULL
and	NULL
upstream	NULL
from	NULL
Activation	NULL
of	NULL
NFkB	NULL
by	NULL
TRAIL	NULL
was	NULL
not	NULL
found	NULL
in	NULL
all	NULL
lymphoid	NULL
cell	NULL
lines	NULL
sensitive	NULL
for	NULL
TRAIL-induced	NULL
apoptosis	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
cell	NULL
type	NULL
specificity	NULL
of	NULL
TRAIL-mediated	NULL
NFKB	NULL
activation	NULL
has	NULL
also	NULL
been	NULL
described	NULL
in	NULL
some	NULL
,	NULL
but	NULL
not	NULL
all	NULL
solid	NULL
tumor	NULL
cell	NULL
lines	NULL
.	NULL
``	NULL

''	NULL
However	NULL
,	NULL
all	NULL
DILs	NULL
identified	NULL
so	NULL
far	NULL
are	NULL
able	NULL
to	NULL
mediate	NULL
at	NULL
least	NULL
two	NULL
different	NULL
signals	NULL
in	NULL
some	NULL
cells	NULL
,	NULL
apoptosis	NULL
and	NULL
activation	NULL
of	NULL
NFB	NULL
.	NULL

We	NULL
studied	NULL
the	NULL
influence	NULL
of	NULL
NFB	NULL
on	NULL
induction	NULL
of	NULL
apoptosis	NULL
using	NULL
two	NULL
different	NULL
approaches	NULL
to	NULL
block	NULL
NFKB	NULL
activation	NULL
.	NULL

LLnL	NULL
disables	NULL
degradation	NULL
of	NULL
NFB-inhibitory	NULL
IxBa	NULL
protein	NULL
by	NULL
the	NULL
proteasome	NULL
.	NULL

Because	NULL
inhibition	NULL
of	NULL
proteasome	NULL
function	NULL
itself	NULL
may	NULL
have	NULL
potential	NULL
side	NULL
effects	NULL
,	NULL
``	NULL
``	NULL
``	NULL
``	NULL
we	NULL
performed	NULL
an	NULL
extensive	NULL
testing	NULL
for	NULL
the	NULL
toxicity	NULL
of	NULL
LLnL	NULL
.	NULL

The	NULL
cell-type-specific	NULL
LLnL	NULL
dosages	NULL
used	NULL
in	NULL
our	NULL
experiments	NULL
were	NULL
well	NULL
beneath	NULL
the	NULL
cell-type	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

INHIBITION	NULL
OF	NULL
NFkB	NULL
ATTENUATES	NULL
APOPTOSIS	NULL
RESISTANCE	NULL
A	NULL
*	NULL
1	NULL
Fig	NULL
5	NULL
.	NULL

Attenuation	NULL
of	NULL
apoptosis	NULL
resistance	NULL
in	NULL
primary	NULL
leukemia	NULL
cells	NULL
by	NULL
inhibition	NULL
of	NULL
NFB	NULL
activation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Primary	NULL
leukemia	NULL
cells	NULL
of	NULL
6	NULL
patients	NULL
with	NULL
acute	NULL
leukemias	NULL
were	NULL
obtained	NULL
from	NULL
bone	NULL
marrow	NULL
at	NULL
the	NULL
time	NULL
of	NULL
diagnosis	NULL
and	NULL
separated	NULL
by	NULL
Ficoll	NULL
gradient	NULL
centrifugation	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
TRAIL	NULL
(	NULL
1	NULL
pg/mL	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
LLnL	NULL
(	NULL
1	NULL
hour	NULL
of	NULL
preincubation	NULL
,	NULL
untoxic	NULL
dosis	NULL
,	NULL
respectively	NULL
,	NULL
for	NULL
each	NULL
patient	NULL
,	NULL
4	NULL
to	NULL
25	NULL
pmol/L	NULL
)	NULL
for	NULL
6	NULL
to	NULL
12	NULL
hours	NULL
(	NULL
spontaneous	NULL
apoptosis	NULL
<	NULL
35	NULL
%	NULL
)	NULL
and	NULL
apoptosis	NULL
was	NULL
measured	NULL
by	NULL
forward	NULL
side	NULL
scatter	NULL
analysis	NULL
in	NULL
FACScan	NULL
flow	NULL
cytom-eter	NULL
.	NULL

Data	NULL
are	NULL
the	NULL
mean	NULL
of	NULL
duplicates	NULL
with	NULL
a	NULL
standard	NULL
deviation	NULL
less	NULL
than	NULL
10	NULL
%	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Primary	NULL
bone	NULL
marrow	NULL
leukemia	NULL
cells	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
common	NULL
ALL	NULL
were	NULL
obtained	NULL
as	NULL
in	NULL
(	NULL
A	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
with	NULL
TRAIL	NULL
(	NULL
1	NULL
pg/mL	NULL
)	NULL
,	NULL
anti-APO-1	NULL
(	NULL
1	NULL
pg/mL	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
protein	NULL
A	NULL
(	NULL
5	NULL
ng/mL	NULL
)	NULL
,	NULL
or	NULL
TNFa	NULL
(	NULL
0,3	NULL
pg/mL	NULL
)	NULL
for	NULL
6	NULL
hours	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
LLnL	NULL
(	NULL
4.25	NULL
pmol/L	NULL
,	NULL
1	NULL
hour	NULL
of	NULL
preincu-bation	NULL
)	NULL
,	NULL
and	NULL
apoptosis	NULL
was	NULL
measured	NULL
as	NULL
in	NULL
(	NULL
A	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
the	NULL
mean	NULL
of	NULL
duplicates	NULL
with	NULL
a	NULL
standard	NULL
0	NULL
deviation	NULL
less	NULL
than	NULL
10	NULL
%	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
two	NULL
patients	NULL
.	NULL

17,5	NULL
+	NULL
specific	NULL
apoptosis	NULL
(	NULL
%	NULL
)	NULL
specific	NULL
toxicity	NULL
limit	NULL
of	NULL
the	NULL
drug	NULL
(	NULL
10	NULL
to	NULL
20	NULL
umol/L	NULL
,	NULL
respec-tively	NULL
)	NULL
.	NULL

LLnL	NULL
significantly	NULL
increased	NULL
induction	NULL
of	NULL
apoptosis	NULL
by	NULL
DILs	NULL
and	NULL
doxorubicin	NULL
.	NULL

To	NULL
rule	NULL
out	NULL
that	NULL
the	NULL
increase	NULL
in	NULL
induction	NULL
of	NULL
apoptosis	NULL
might	NULL
be	NULL
due	NULL
to	NULL
interference	NULL
of	NULL
proteasome	NULL
inhibitor	NULL
with	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
``	NULL
a	NULL
second	NULL
molecular	NULL
approach	NULL
was	NULL
performed	NULL
using	NULL
transfection	NULL
of	NULL
DNA	NULL
encoding	NULL
mutant	NULL
IxBa	NULL
protein	NULL
.	NULL

The	NULL
mutant	NULL
IxBa	NULL
protein	NULL
can	NULL
not	NULL
be	NULL
phosphorylated	NULL
and	NULL
subsequentially	NULL
ubiquitinated	NULL
,	NULL
leading	NULL
to	NULL
inhibition	NULL
of	NULL
NFB	NULL
activity	NULL
.	NULL

Overexpression	NULL
of	NULL
mutant	NULL
IxBa	NULL
markedly	NULL
increased	NULL
induction	NULL
of	NULL
apoptosis	NULL
,	NULL
proving	NULL
that	NULL
NFB	NULL
activation	NULL
interferes	NULL
with	NULL
DIL-induced	NULL
apoptosis	NULL
in	NULL
lymphoid	NULL
cells	NULL
,	NULL
eg	NULL
,	NULL
after	NULL
stimulation	NULL
with	NULL
TRAIL	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
by	NULL
transient	NULL
overexpression	NULL
of	NULL
wild-type	NULL
IxBa	NULL
protein	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Most	NULL
importantly	NULL
,	NULL
inhibition	NULL
of	NULL
NFB	NULL
activation	NULL
enabled	NULL
apoptosis	NULL
sensitivity	NULL
for	NULL
all	NULL
DILs	NULL
in	NULL
otherwise	NULL
apoptosis-resistant	NULL
CEM-R	NULL
cells	NULL
.	NULL

CEM-R	NULL
cells	NULL
were	NULL
derived	NULL
from	NULL
the	NULL
apoptosis-sensitive	NULL
parental	NULL
CEM	NULL
cell	NULL
line	NULL
by	NULL
continuous	NULL
culture	NULL
in	NULL
doxorubicin	NULL
for	NULL
several	NULL
months	NULL
.	NULL
``	NULL

''	NULL
CEM-R	NULL
cells	NULL
did	NULL
not	NULL
exhibit	NULL
an	NULL
MDR	NULL
phenotype	NULL
of	NULL
drug	NULL
resistance	NULL
and	NULL
were	NULL
cross-resistant	NULL
to	NULL
apoptosis	NULL
induction	NULL
by	NULL
several	NULL
DILs	NULL
.	NULL

CEM-R	NULL
cells	NULL
showed	NULL
a	NULL
similar	NULL
basal	NULL
NFKB	NULL
activity	NULL
,	NULL
similar	NULL
p65	NULL
content	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
and	NULL
similar	NULL
TRAIL-mediated	NULL
NFB	NULL
activation	NULL
compared	NULL
with	NULL
CEM	NULL
cells	NULL
,	NULL
but	NULL
a	NULL
slightly	NULL
increased	NULL
sensitivity	NULL
for	NULL
LLnL	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
these	NULL
cells	NULL
,	NULL
inhibition	NULL
of	NULL
NFB	NULL
activation	NULL
significantly	NULL
attenuated	NULL
apoptosis	NULL
resistance	NULL
towards	NULL
DILs	NULL
and	NULL
doxorubicin	NULL
,	NULL
predominantly	NULL
for	NULL
TRAIL	NULL
and	NULL
TNFa	NULL
.	NULL

Activation	NULL
of	NULL
NFB	NULL
has	NULL
been	NULL
found	NULL
after	NULL
treatment	NULL
of	NULL
tumor	NULL
cells	NULL
with	NULL
cytostatic	NULL
drugs	NULL
.	NULL

'*	NULL
``	NULL
``	NULL
In	NULL
cells	NULL
cross-resistant	NULL
for	NULL
DIL	NULL
and	NULL
drug-induced	NULL
apoptosis	NULL
,	NULL
inhibition	NULL
of	NULL
NFB	NULL
activation	NULL
by	NULL
LLnL	NULL
sensitizes	NULL
for	NULL
both	NULL
DILs	NULL
and	NULL
drugs	NULL
.	NULL

Recent	NULL
evidence	NULL
suggests	NULL
that	NULL
induction	NULL
of	NULL
apoptosis	NULL
in	NULL
target	NULL
cells	NULL
by	NULL
cytostatic	NULL
drugs	NULL
may	NULL
involve	NULL
DILs	NULL
such	NULL
as	NULL
the	NULL
CD95	NULL
system	NULL
.	NULL
``	NULL

''	NULL
Drugs	NULL
also	NULL
increase	NULL
cellular	NULL
TRAIL	NULL
mRNA	NULL
and	NULL
TNFa	NULL
mRNA*	NULL
(	NULL
Herr	NULL
et	NULL
al	NULL
,	NULL
manuscript	NULL
submitted	NULL
)	NULL
,	NULL
suggesting	NULL
a	NULL
possible	NULL
additional	NULL
role	NULL
for	NULL
TRAIL	NULL
and	NULL
TNFa	NULL
:	NULL
in	NULL
drug-induced	NULL
apoptosis	NULL
.	NULL

Because	NULL
induction	NULL
of	NULL
apoptosis	NULL
by	NULL
anticancer	NULL
drugs	NULL
may	NULL
involve	NULL
DILs,4	NULL
``	NULL
activation	NULL
of	NULL
NFB	NULL
after	NULL
drug	NULL
treatment	NULL
may	NULL
be	NULL
a	NULL
consequence	NULL
TRAIL	NULL
4629	NULL
)	NULL
A	NULL
S	NULL
10	NULL
4	NULL
specific	NULL
apoptosis	NULL
(	NULL
%	NULL
LLnL	NULL
+	NULL
|	NULL
+	NULL
£	NULL
4	NULL
ThiFc	NULL
[	NULL
+	NULL
]	NULL
+	NULL
TRAIL	NULL
+LLnL	NULL
of	NULL
DIL	NULL
function	NULL
.	NULL

Thus	NULL
,	NULL
LLnL	NULL
might	NULL
overcome	NULL
drug	NULL
resistance	NULL
by	NULL
sensitizing	NULL
for	NULL
DIL-induced	NULL
apoptosis	NULL
.	NULL

The	NULL
concept	NULL
that	NULL
inhibition	NULL
of	NULL
NFB	NULL
activation	NULL
increases	NULL
apoptosis	NULL
sensitivity	NULL
was	NULL
also	NULL
investigated	NULL
in	NULL
primary	NULL
tumor	NULL
cells	NULL
of	NULL
patients	NULL
with	NULL
acute	NULL
leukemias	NULL
ex	NULL
vivo	NULL
.	NULL

Although	NULL
no	NULL
specific	NULL
apoptosis	NULL
was	NULL
induced	NULL
using	NULL
DIL	NULL
alone	NULL
,	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
specific	NULL
cell	NULL
death	NULL
could	NULL
be	NULL
obtained	NULL
by	NULL
TRAIL	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
LLnL	NULL
in	NULL
5	NULL
of	NULL
6	NULL
patients	NULL
.	NULL

Recently	NULL
,	NULL
it	NULL
was	NULL
suggested	NULL
that	NULL
apoptosis	NULL
resistance	NULL
for	NULL
TRAIL	NULL
might	NULL
be	NULL
based	NULL
on	NULL
presence	NULL
of	NULL
two	NULL
TRAIL	NULL
receptors	NULL
that	NULL
contain	NULL
an	NULL
absent	NULL
or	NULL
truncated	NULL
intracellular	NULL
signal	NULL
transducing	NULL
death	NULL
domain	NULL
(	NULL
TRAIL-R3	NULL
,	NULL
TRID	NULL
,	NULL
DeR1	NULL
,	NULL
LIT,262730344445	NULL
and	NULL
TRAIL-R4	NULL
,	NULL
DeR2454	NULL
)	NULL
,	NULL
The	NULL
distribution	NULL
pattern	NULL
of	NULL
TRAIL-R3	NULL
suggested	NULL
that	NULL
normal	NULL
,	NULL
but	NULL
not	NULL
malignant	NULL
cells	NULL
were	NULL
resistant	NULL
towards	NULL
TRAIL-induced	NULL
apoptosis	NULL
.	NULL

In	NULL
line	NULL
with	NULL
this	NULL
,	NULL
we	NULL
found	NULL
that	NULL
normal	NULL
peripheral	NULL
T	NULL
cells	NULL
remain	NULL
resistant	NULL
towards	NULL
TRAIL-induced	NULL
apoptosis	NULL
even	NULL
after	NULL
activation	NULL
.	NULL
``	NULL

Additionally	NULL
,	NULL
the	NULL
majority	NULL
of	NULL
leukemic	NULL
cell	NULL
lines	NULL
tested	NULL
display	NULL
a	NULL
TRAIL-sensitive	NULL
phenotype	NULL
.	NULL

``	NULL
>	NULL
*	NULL
``	NULL
However	NULL
,	NULL
all	NULL
primary	NULL
leukemia	NULL
cells	NULL
used	NULL
here	NULL
were	NULL
almost	NULL
completely	NULL
resistant	NULL
towards	NULL
TRAIL-induced	NULL
apoptosis	NULL
.	NULL

Because	NULL
LLnL	NULL
sensitizes	NULL
patient	NULL
cells	NULL
for	NULL
TRAIL-induced	NULL
apoptosis	NULL
,	NULL
the	NULL
molecular	NULL
mechanism	NULL
of	NULL
apoptosis	NULL
resistance	NULL
seems	NULL
to	NULL
be	NULL
more	NULL
complex	NULL
and	NULL
might	NULL
additionally	NULL
involve	NULL
intracellular	NULL
signal	NULL
proteins	NULL
that	NULL
may	NULL
at	NULL
least	NULL
partially	NULL
depend	NULL
on	NULL
NFkB	NULL
activity	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
activation	NULL
of	NULL
NFB	NULL
antagonizes	NULL
induction	NULL
of	NULL
apoptosis	NULL
remains	NULL
to	NULL
be	NULL
elucidated	NULL
.	NULL

Coincubstion	NULL
of	NULL
TRAIL	NULL
,	NULL
CD95-L	NULL
,	NULL
or	NULL
TNFa	NULL
with	NULL
an	NULL
inhibitor	NULL
of	NULL
protein	NULL
synthesis	NULL
,	NULL
eg	NULL
,	NULL
cycloheximide	NULL
,	NULL
also	NULL
augments	NULL
induction	NULL
of	NULL
apoptosis	NULL
and	NULL
attenuates	NULL
apoptosis	NULL
resistance	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
protects	NULL
cells	NULL
from	NULL
DIL-induced	NULL
cytotoxicity	NULL
probably	NULL
by	NULL
induction	NULL
of	NULL
protective	NULL
genes	NULL
eventually	NULL
mediated	NULL
by	NULL
NFkB	NULL
.	NULL

NFkB-dependent	NULL
proteins	NULL
might	NULL
interfere	NULL
with	NULL
pathways	NULL
leading	NULL
to	NULL
caspase	NULL
activation	NULL
and	NULL
might	NULL
participate	NULL
in	NULL
generating	NULL
abundant	NULL
cross-resistances	NULL
between	NULL
different	NULL
apoptosis-inducing	NULL
agents	NULL
.	NULL

Further	NULL
studies	NULL
are	NULL
needed	NULL
to	NULL
detect	NULL
the	NULL
effectors	NULL
of	NULL
the	NULL
NFKB	NULL
activation	NULL
signal	NULL
as	NULL
well	NULL
as	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

4630	NULL
the	NULL
therapeutic	NULL
potential	NULL
of	NULL
interference	NULL
with	NULL
NFKB	NULL
to	NULL
overcome	NULL
apoptosis	NULL
resistance	NULL
in	NULL
clinical	NULL
settings	NULL
.	NULL

ACKNOWLEDGMENT	NULL
The	NULL
authors	NULL
thank	NULL
C.	NULL
Friesen	NULL
for	NULL
providing	NULL
CEM-R	NULL
and	NULL
Jurkat-R	NULL
cells	NULL
and	NULL
D.	NULL
Suess	NULL
,	NULL
R.	NULL
Zucic	NULL
,	NULL
and	NULL
E.	NULL
Musiol	NULL
for	NULL
excellent	NULL
technical	NULL
help	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Burnett	NULL
AK	NULL
,	NULL
Eden	NULL
OB	NULL
:	NULL
The	NULL
treatment	NULL
of	NULL
acute	NULL
leukaemia	NULL
.	NULL

Lancet	NULL
349:270	NULL
,	NULL
1997	NULL
2	NULL
.	NULL

Bacuerle	NULL
PA	NULL
,	NULL
Henkel	NULL
T	NULL
:	NULL
Function	NULL
and	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

Annu	NULL
Rev	NULL
Immunol	NULL
12:141	NULL
,	NULL
1994	NULL
3	NULL
.	NULL

Baldwin	NULL
AS	NULL
:	NULL
The	NULL
NF-kB	NULL
and	NULL
IB	NULL
proteins	NULL
:	NULL
New	NULL
discoveries	NULL
and	NULL
insights	NULL
.	NULL

Annu	NULL
Rev	NULL
Immunol	NULL
14:649	NULL
,	NULL
1996	NULL
4	NULL
.	NULL

Beg	NULL
AA	NULL
,	NULL
Sha	NULL
WC	NULL
,	NULL
Bronson	NULL
RT	NULL
,	NULL
Ghosh	NULL
S	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
Embryonic	NULL
lethality	NULL
and	NULL
liver	NULL
degeneration	NULL
in	NULL
mice	NULL
lacking	NULL
the	NULL
RelA	NULL
component	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Nature	NULL
376:167	NULL
,	NULL
1995	NULL
5	NULL
.	NULL

Bacuerle	NULL
PA	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
Ten	NULL
years	NULL
after	NULL
.	NULL

Cell	NULL
87:13	NULL
,	NULL
1996	NULL
6	NULL
.	NULL

Verma	NULL
IM	NULL
,	NULL
Stevenson	NULL
JK	NULL
,	NULL
Schwarz	NULL
EM	NULL
,	NULL
vanAntwerp	NULL
D	NULL
,	NULL
Miya-moto	NULL
S	NULL
:	NULL
Rel/NF-	NULL
«	NULL
B/I	NULL
«	NULL
B	NULL
family	NULL
:	NULL
Intimate	NULL
tales	NULL
of	NULL
association	NULL
and	NULL
dissociation	NULL
.	NULL

Genes	NULL
Dev	NULL
9:2723	NULL
,	NULL
1995	NULL
7	NULL
.	NULL

Thanos	NULL
D	NULL
,	NULL
Maniatis	NULL
T	NULL
:	NULL
NF-kB	NULL
:	NULL
A	NULL
lesson	NULL
in	NULL
family	NULL
values	NULL
.	NULL

Cell	NULL
80:529	NULL
,	NULL
1995	NULL
8	NULL
.	NULL

Roff	NULL
M	NULL
,	NULL
Thompson	NULL
J	NULL
,	NULL
Rodriguez	NULL
MS	NULL
,	NULL
Jacque	NULL
JM	NULL
,	NULL
Baleux	NULL
F	NULL
,	NULL
Arenzana-Seisdedos	NULL
F	NULL
,	NULL
Hay	NULL
RT	NULL
:	NULL
Role	NULL
of	NULL
I	NULL
<	NULL
Ba	NULL
«	NULL
ubiquitination	NULL
in	NULL
signal-induced	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
vivo	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
271:7844	NULL
,	NULL
1996	NULL
9	NULL
.	NULL

Henkel	NULL
T	NULL
,	NULL
Machleidt	NULL
T	NULL
,	NULL
Alkalay	NULL
I	NULL
,	NULL
Kroenke	NULL
M	NULL
,	NULL
Ben-Neriah	NULL
Y	NULL
,	NULL
Bacuerle	NULL
PA	NULL
:	NULL
Rapid	NULL
proteolysis	NULL
of	NULL
IxB-	NULL
«	NULL
is	NULL
necessary	NULL
for	NULL
activation	NULL
of	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Nature	NULL
365:182	NULL
,	NULL
1993	NULL
10	NULL
.	NULL

Beg	NULL
AA	NULL
,	NULL
Baldwin	NULL
AS	NULL
:	NULL
The	NULL
IxB	NULL
proteins	NULL
:	NULL
Multifunctional	NULL
regulators	NULL
of	NULL
Rel/NF-	NULL
<	NULL
B	NULL
transcription	NULL
factors	NULL
.	NULL

Genes	NULL
Dev	NULL
7:2064	NULL
,	NULL
1993	NULL
11	NULL
.	NULL

Chen	NULL
Z	NULL
,	NULL
Hagler	NULL
J	NULL
,	NULL
Palombella	NULL
VJ	NULL
,	NULL
Melandri	NULL
F	NULL
,	NULL
Scherer	NULL
D	NULL
,	NULL
Ballard	NULL
D	NULL
,	NULL
Maniatis	NULL
T	NULL
:	NULL
Signal-induced	NULL
site-specific	NULL
phosphorylation	NULL
targets	NULL
IxBa	NULL
to	NULL
the	NULL
ubiquitin-proteasome	NULL
pathway	NULL
.	NULL

Genes	NULL
Dev	NULL
9:1	NULL
586	NULL
,	NULL
1995	NULL
12	NULL
.	NULL

Beg	NULL
AA	NULL
,	NULL
Ruben	NULL
SM	NULL
,	NULL
Scheinman	NULL
RI	NULL
,	NULL
Haskill	NULL
S	NULL
,	NULL
Rosen	NULL
CA	NULL
,	NULL
Baldwin	NULL
AS	NULL
:	NULL
IxB	NULL
interacts	NULL
with	NULL
the	NULL
nuclear	NULL
localization	NULL
sequences	NULL
of	NULL
the	NULL
subunits	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
A	NULL
mechanism	NULL
for	NULL
cytoplasmic	NULL
retention	NULL
.	NULL

Genes	NULL
Dev	NULL
6:1899	NULL
,	NULL
1992	NULL
13	NULL
.	NULL

Palombella	NULL
VJ	NULL
,	NULL
Rando	NULL
OJ	NULL
,	NULL
Goldberg	NULL
AL	NULL
,	NULL
Maniatis	NULL
T	NULL
:	NULL
The	NULL
ubiquitin-proteasome	NULL
pathway	NULL
is	NULL
required	NULL
for	NULL
processing	NULL
the	NULL
NF-	NULL
«	NULL
B1	NULL
precursor	NULL
protein	NULL
and	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Cell	NULL
78:773	NULL
,	NULL
1994	NULL
14	NULL
.	NULL

Boland	NULL
MP	NULL
,	NULL
Foster	NULL
SJ	NULL
,	NULL
ONeill	NULL
LAJ	NULL
:	NULL
Daunorubicin	NULL
activates	NULL
NFB	NULL
and	NULL
induces	NULL
«	NULL
B-dependent	NULL
gene	NULL
expression	NULL
in	NULL
HL-60	NULL
promyelo-cytic	NULL
and	NULL
Jurkat	NULL
T	NULL
lymphoma	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:12952	NULL
,	NULL
1997	NULL
15	NULL
.	NULL

Das	NULL
KC	NULL
,	NULL
White	NULL
CW	NULL
:	NULL
Activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
antineoplastic	NULL
agents	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:14914	NULL
,	NULL
1997	NULL
16	NULL
.	NULL

Malinin	NULL
NL	NULL
,	NULL
Boldin	NULL
MP	NULL
,	NULL
Kovalenko	NULL
AV	NULL
,	NULL
Wallach	NULL
D	NULL
:	NULL
MAP3K-related	NULL
kinase	NULL
involved	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
induction	NULL
by	NULL
TNF	NULL
,	NULL
CD95	NULL
and	NULL
IL-1	NULL
.	NULL

Nature	NULL
385:540	NULL
,	NULL
1997	NULL
17	NULL
.	NULL

Wang	NULL
CY	NULL
,	NULL
Mayo	NULL
MW	NULL
,	NULL
Baldwin	NULL
AS	NULL
:	NULL
TNF-	NULL
and	NULL
cancer	NULL
therapy-induced	NULL
apoptosis	NULL
:	NULL
Potentiation	NULL
by	NULL
inhibition	NULL
of	NULL
NF-kB	NULL
.	NULL

Science	NULL
274:784	NULL
,	NULL
1996	NULL
18	NULL
.	NULL

Wu	NULL
M	NULL
,	NULL
Lee	NULL
H	NULL
,	NULL
Bellas	NULL
RE	NULL
,	NULL
Schauer	NULL
SL	NULL
,	NULL
Arsura	NULL
M	NULL
,	NULL
Katz	NULL
D	NULL
,	NULL
FitzGerald	NULL
MJ	NULL
,	NULL
Rothstein	NULL
TL	NULL
,	NULL
Sherr	NULL
DH	NULL
,	NULL
Sonenshein	NULL
GE	NULL
:	NULL
Inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B/Re	NULL
!	NULL

l	NULL
induces	NULL
apoptosis	NULL
of	NULL
murine	NULL
B	NULL
cells	NULL
.	NULL

EMBO	NULL
J	NULL
15:4682	NULL
,	NULL
1996	NULL
19	NULL
.	NULL

Beg	NULL
AA	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
An	NULL
essential	NULL
role	NULL
of	NULL
NF-B	NULL
in	NULL
preventing	NULL
TNF-	NULL
«	NULL
-induced	NULL
cell	NULL
death	NULL
.	NULL

Science	NULL
274:782	NULL
,	NULL
1996	NULL
20	NULL
.	NULL

Antwerp	NULL
DJV	NULL
,	NULL
Martin	NULL
SJ	NULL
,	NULL
Kafri	NULL
T	NULL
,	NULL
Green	NULL
DR	NULL
,	NULL
Verma	NULL
IM	NULL
:	NULL
Suppression	NULL
of	NULL
TNF-	NULL
«	NULL
-induced	NULL
apoptosis	NULL
by	NULL
NF-kB	NULL
.	NULL

Science	NULL
274:787	NULL
,	NULL
1996	NULL
21	NULL
.	NULL

Ponton	NULL
A	NULL
,	NULL
Clement	NULL
MV	NULL
,	NULL
Stamenkovie	NULL
I	NULL
:	NULL
The	NULL
CD95	NULL
(	NULL
APO-1/Fas	NULL
)	NULL
JEREMIAS	NULL
ET	NULL
AL	NULL
receptor	NULL
activates	NULL
NF-	NULL
«	NULL
B	NULL
independently	NULL
of	NULL
its	NULL
cytotoxic	NULL
function	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
271:8991	NULL
,	NULL
1996	NULL
22	NULL
.	NULL

Wiley	NULL
SR	NULL
,	NULL
Schooley	NULL
K	NULL
,	NULL
Smolak	NULL
PJ	NULL
,	NULL
Din	NULL
WS	NULL
,	NULL
Huang	NULL
CP	NULL
,	NULL
Nicholi	NULL
JK	NULL
,	NULL
Sutherland	NULL
GR	NULL
,	NULL
Smith	NULL
TD	NULL
,	NULL
Rauch	NULL
C	NULL
,	NULL
Smith	NULL
CA	NULL
,	NULL
Goodwin	NULL
RG	NULL
:	NULL
Identification	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
TNF	NULL
family	NULL
that	NULL
induces	NULL
apoptosis	NULL
.	NULL

Immunity	NULL
3:673	NULL
,	NULL
1995	NULL
23	NULL
.	NULL

Pitti	NULL
RM	NULL
,	NULL
Marsters	NULL
SA	NULL
,	NULL
Ruppert	NULL
S	NULL
,	NULL
Donahue	NULL
CJ	NULL
,	NULL
Moore	NULL
A	NULL
,	NULL
Ashkenazi	NULL
A	NULL
:	NULL
Induction	NULL
of	NULL
apoptosis	NULL
by	NULL
Apo-2	NULL
ligand	NULL
,	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
cytokine	NULL
family	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
271:12687	NULL
,	NULL
1996	NULL
24	NULL
.	NULL

Marsters	NULL
SA	NULL
,	NULL
Pitti	NULL
RM	NULL
,	NULL
Donahue	NULL
CJ	NULL
,	NULL
Ruppert	NULL
S	NULL
,	NULL
Bauer	NULL
KD	NULL
,	NULL
Ashkenazi	NULL
A	NULL
:	NULL
Activation	NULL
of	NULL
apoptosis	NULL
by	NULL
Apo-2	NULL
ligand	NULL
is	NULL
independent	NULL
of	NULL
FADD	NULL
but	NULL
blocked	NULL
by	NULL
CrmA	NULL
.	NULL

Curr	NULL
Biol	NULL
6:750	NULL
,	NULL
1996	NULL
25	NULL
.	NULL

Pan	NULL
G	NULL
,	NULL
ORourke	NULL
K	NULL
,	NULL
Chinnaiyan	NULL
AM	NULL
,	NULL
Gentz	NULL
R	NULL
,	NULL
Ebner	NULL
R	NULL
,	NULL
Ni	NULL
J	NULL
,	NULL
Dixit	NULL
VM	NULL
:	NULL
The	NULL
receptor	NULL
for	NULL
the	NULL
cytotoxic	NULL
ligand	NULL
TRAIL	NULL
.	NULL

Science	NULL
276:111	NULL
,	NULL
1997	NULL
26	NULL
.	NULL

Pan	NULL
G	NULL
,	NULL
Ni	NULL
J	NULL
,	NULL
Wei	NULL
YF	NULL
,	NULL
Yu	NULL
GL	NULL
,	NULL
Gentz	NULL
R	NULL
,	NULL
Dixit	NULL
VM	NULL
:	NULL
An	NULL
antagonist	NULL
decoy	NULL
receptor	NULL
and	NULL
a	NULL
death	NULL
domain-containing	NULL
receptor	NULL
for	NULL
TRAIL	NULL
.	NULL

Science	NULL
277:815	NULL
,	NULL
1997	NULL
27	NULL
.	NULL

Sheridan	NULL
JP	NULL
,	NULL
Marsters	NULL
SA	NULL
,	NULL
Pitti	NULL
RM	NULL
,	NULL
Gurney	NULL
A	NULL
,	NULL
Skubatch	NULL
M	NULL
,	NULL
Baldwin	NULL
D	NULL
,	NULL
Ramakrishnan	NULL
L	NULL
,	NULL
Gray	NULL
CL	NULL
,	NULL
Baker	NULL
K	NULL
,	NULL
Wood	NULL
WI	NULL
,	NULL
Goddard	NULL
AD	NULL
,	NULL
Godowski	NULL
P	NULL
,	NULL
Ashkenazi	NULL
A	NULL
:	NULL
Control	NULL
of	NULL
TRAIL-induced	NULL
apoptosis	NULL
by	NULL
a	NULL
family	NULL
of	NULL
signaling	NULL
and	NULL
decoy	NULL
receptors	NULL
.	NULL

Science	NULL
277:818	NULL
,	NULL
1997	NULL
28	NULL
.	NULL

Screaton	NULL
GR	NULL
,	NULL
Mongkolsapaya	NULL
J	NULL
,	NULL
Xu	NULL
XN	NULL
,	NULL
Cowper	NULL
AE	NULL
,	NULL
McMichael	NULL
AJ	NULL
,	NULL
Bell	NULL
JI	NULL
;	NULL
TRICK2	NULL
,	NULL
a	NULL
new	NULL
alternatively	NULL
spliced	NULL
receptor	NULL
that	NULL
transduces	NULL
the	NULL
cytotoxic	NULL
signal	NULL
from	NULL
TRAIL	NULL
.	NULL

Curr	NULL
Biol	NULL
7:693	NULL
,	NULL
1997	NULL
29	NULL
.	NULL

Walczak	NULL
H	NULL
,	NULL
Degli-Esposti	NULL
MA	NULL
,	NULL
Johnson	NULL
RS	NULL
,	NULL
Smolak	NULL
PJ	NULL
,	NULL
Waugh	NULL
JY	NULL
,	NULL
Boiani	NULL
N	NULL
,	NULL
Timour	NULL
MS	NULL
,	NULL
Gerhart	NULL
MJ	NULL
,	NULL
Schooley	NULL
KA	NULL
,	NULL
Smith	NULL
CA	NULL
,	NULL
Goodwin	NULL
RG	NULL
,	NULL
Rauch	NULL
CT	NULL
:	NULL
TRAIL-R2	NULL
:	NULL
A	NULL
novel	NULL
apoptosis-mediating	NULL
receptor	NULL
for	NULL
TRAIL	NULL
.	NULL

EMBO	NULL
J	NULL
16:5386	NULL
,	NULL
1997	NULL
30	NULL
.	NULL

MacFarlane	NULL
M	NULL
,	NULL
Abmad	NULL
M	NULL
,	NULL
Srinivasula	NULL
SM	NULL
,	NULL
Fernandes-Alnermri	NULL
T	NULL
,	NULL
Cohen	NULL
GM	NULL
,	NULL
Alnemri	NULL
ES	NULL
:	NULL
Identification	NULL
and	NULL
molecular	NULL
cloning	NULL
of	NULL
two	NULL
novel	NULL
receptors	NULL
for	NULL
the	NULL
cytotoxic	NULL
ligand	NULL
TRAIL	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272	NULL
:	NULL
25417	NULL
,	NULL
1997	NULL
31	NULL
.	NULL

Degli-Esposti	NULL
MA	NULL
,	NULL
Smolak	NULL
PJ	NULL
,	NULL
Walczak	NULL
H	NULL
,	NULL
Waugh	NULL
JY	NULL
,	NULL
Huang	NULL
CP	NULL
,	NULL
DuBose	NULL
RF	NULL
,	NULL
Goodwin	NULL
RG	NULL
,	NULL
Smith	NULL
CA	NULL
:	NULL
Cloning	NULL
and	NULL
characterization	NULL
of	NULL
TRAIL-R3	NULL
,	NULL
a	NULL
novel	NULL
member	NULL
of	NULL
the	NULL
emerging	NULL
TRAIL	NULL
receptor	NULL
family	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
186:1165	NULL
,	NULL
1997	NULL
32	NULL
.	NULL

Jeremias	NULL
I	NULL
,	NULL
Herr	NULL
I	NULL
,	NULL
Boehler	NULL
T	NULL
,	NULL
Debatin	NULL
KM	NULL
:	NULL
TRAIL/Apo-2-Ligand	NULL
induced	NULL
apoptosis	NULL
in	NULL
T-cells	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
28:143	NULL
,	NULL
1998	NULL
33	NULL
.	NULL

Rensing-Ehl	NULL
A	NULL
,	NULL
Hess	NULL
S	NULL
,	NULL
Ziegler-Heitbrock	NULL
HWL	NULL
,	NULL
Ricthmueller	NULL
G	NULL
,	NULL
Engelmann	NULL
H	NULL
:	NULL
Fas/Apo-1	NULL
activates	NULL
nuclear	NULL
factor	NULL
xB	NULL
and	NULL
induces	NULL
interleukin-6	NULL
production	NULL
.	NULL

J	NULL
Inflamm	NULL
45:161	NULL
,	NULL
1995	NULL
34	NULL
.	NULL

Chaudhary	NULL
PM	NULL
,	NULL
Eby	NULL
M	NULL
,	NULL
Jasmin	NULL
A	NULL
,	NULL
Bookwalter	NULL
A	NULL
,	NULL
Murray	NULL
J	NULL
,	NULL
Hood	NULL
L	NULL
:	NULL
Death	NULL
receptor	NULL
5	NULL
,	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
TNFR	NULL
family	NULL
,	NULL
and	NULL
DR4	NULL
induce	NULL
FADD-dependent	NULL
apoptosis	NULL
and	NULL
activate	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
pathway	NULL
.	NULL

Immunity	NULL
7:821	NULL
,	NULL
1997	NULL
35	NULL
.	NULL

Schneider	NULL
P	NULL
,	NULL
Thome	NULL
M	NULL
,	NULL
Burns	NULL
K	NULL
,	NULL
Bodmer	NULL
JL	NULL
,	NULL
Hofmann	NULL
K	NULL
,	NULL
Kataoka	NULL
T	NULL
,	NULL
Holler	NULL
N	NULL
,	NULL
Tschopp	NULL
J	NULL
:	NULL
TRAIL	NULL
receptors	NULL
1	NULL
(	NULL
DR4	NULL
)	NULL
and	NULL
2	NULL
(	NULL
DR5	NULL
)	NULL
signal	NULL
FADD-dependent	NULL
apoptosis	NULL
and	NULL
activate	NULL
NF-kB	NULL
.	NULL

Immunity	NULL
7:831	NULL
,	NULL
1997	NULL
36	NULL
.	NULL

Wajant	NULL
H	NULL
,	NULL
Johannes	NULL
FJ	NULL
,	NULL
Haas	NULL
E	NULL
,	NULL
Siemienski	NULL
K	NULL
,	NULL
Schwenzer	NULL
R	NULL
,	NULL
Schubert	NULL
G	NULL
,	NULL
Weiss	NULL
T	NULL
,	NULL
Grell	NULL
M	NULL
,	NULL
Scheurich	NULL
P	NULL
:	NULL
Dominant-negative	NULL
FADD	NULL
inhibits	NULL
TNFR60-	NULL
,	NULL
Fas/Apol-	NULL
and	NULL
TRAIL-R/Apo2-mediated	NULL
cell	NULL
death	NULL
but	NULL
not	NULL
gene	NULL
induction	NULL
.	NULL

Curr	NULL
Biol	NULL
8:113	NULL
,	NULL
1998	NULL
37	NULL
.	NULL

Lu	NULL
Q	NULL
,	NULL
Meligren	NULL
RL	NULL
:	NULL
Calpain	NULL
inhibitors	NULL
and	NULL
serine	NULL
protease	NULL
inhibitors	NULL
can	NULL
produce	NULL
apoptosis	NULL
in	NULL
HL-60	NULL
cells	NULL
.	NULL

Arch	NULL
Biochem	NULL
Biophys	NULL
334:175	NULL
,	NULL
1996	NULL
38	NULL
.	NULL

Shinohara	NULL
K	NULL
,	NULL
Tomioka	NULL
M	NULL
,	NULL
Nakano	NULL
H	NULL
,	NULL
Tone	NULL
S	NULL
,	NULL
Ito	NULL
H	NULL
,	NULL
Kawashima	NULL
S	NULL
:	NULL
Apoptosis	NULL
induction	NULL
resulting	NULL
from	NULL
protease	NULL
inhibition	NULL
.	NULL

Biochem	NULL
J	NULL
317:385	NULL
,	NULL
1996	NULL
39	NULL
.	NULL

Gazos	NULL
Lopez	NULL
U	NULL
,	NULL
Erhardt	NULL
P	NULL
,	NULL
Yao	NULL
R	NULL
,	NULL
Cooper	NULL
GM	NULL
:	NULL
p53-dependent	NULL
induction	NULL
of	NULL
apoptosis	NULL
by	NULL
proteasome	NULL
inhibitors	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272	NULL
:	NULL
12893	NULL
,	NULL
1997	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

INHIBITION	NULL
OF	NULL
NFkB	NULL
ATTENUATES	NULL
APOPTOSIS	NULL
RESISTANCE	NULL
40	NULL
.	NULL

Friesen	NULL
C	NULL
,	NULL
Herr	NULL
I	NULL
,	NULL
Krammer	NULL
PH	NULL
,	NULL
Debatin	NULL
KM	NULL
:	NULL
Involvement	NULL
of	NULL
the	NULL
CD95	NULL
(	NULL
APO-1/Fas	NULL
)	NULL
receptor/ligand	NULL
system	NULL
in	NULL
drug-induced	NULL
apoptosis	NULL
in	NULL
leukemia	NULL
cells	NULL
.	NULL

Nat	NULL
Med	NULL
2:574	NULL
,	NULL
1996	NULL
41	NULL
.	NULL

Fulda	NULL
S	NULL
,	NULL
Sieverts	NULL
H	NULL
,	NULL
Friesen	NULL
C	NULL
,	NULL
Herr	NULL
I	NULL
,	NULL
Debatin	NULL
KM	NULL
:	NULL
The	NULL
CD95	NULL
(	NULL
APO-1/Fas	NULL
)	NULL
system	NULL
mediates	NULL
drug-induced	NULL
apoptosis	NULL
in	NULL
neuroblastoma	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
57:3823	NULL
,	NULL
1997	NULL
42	NULL
.	NULL

Los	NULL
M	NULL
,	NULL
Hetr	NULL
I	NULL
,	NULL
Friesen	NULL
C	NULL
,	NULL
Fulda	NULL
S	NULL
,	NULL
Schulze-Osthoff	NULL
K	NULL
,	NULL
Debatin	NULL
KM	NULL
:	NULL
Cross-resistance	NULL
of	NULL
CD95-	NULL
and	NULL
drug-induced	NULL
apoptosis	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
deficient	NULL
activation	NULL
of	NULL
caspases	NULL
(	NULL
ICE/Ced-3	NULL
proteases	NULL
)	NULL
.	NULL

Blood	NULL
90:3118	NULL
,	NULL
1997	NULL
43	NULL
.	NULL

Bogdan	NULL
C	NULL
,	NULL
Ding	NULL
A	NULL
:	NULL
Taxol	NULL
,	NULL
a	NULL
microtubule-stabilizing	NULL
antineoplastic	NULL
agent	NULL
,	NULL
induces	NULL
expression	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
and	NULL
interleu-kin-1	NULL
in	NULL
macrophages	NULL
.	NULL

J	NULL
Leukoc	NULL
Biol	NULL
52:119	NULL
,	NULL
1992	NULL
44	NULL
.	NULL

Schneider	NULL
P	NULL
,	NULL
Bodmer	NULL
JL	NULL
,	NULL
Thome	NULL
M	NULL
,	NULL
Hofman	NULL
K	NULL
,	NULL
Holler	NULL
N	NULL
,	NULL
Tschopp	NULL
J	NULL
:	NULL
Characterization	NULL
of	NULL
two	NULL
receptors	NULL
for	NULL
TRAIL	NULL
.	NULL

FEBS	NULL
Lett	NULL
416:329	NULL
,	NULL
1997	NULL
4631	NULL
45	NULL
.	NULL

Mongkolsapaya	NULL
J	NULL
,	NULL
Cowper	NULL
AE	NULL
,	NULL
Xu	NULL
XN	NULL
,	NULL
Morris	NULL
G	NULL
,	NULL
McMichael	NULL
AJ	NULL
,	NULL
Bell	NULL
JI	NULL
,	NULL
Screaton	NULL
GR	NULL
:	NULL
Lymphocyte	NULL
inhibitor	NULL
of	NULL
TRAIL	NULL
(	NULL
TNF-related	NULL
apoptosis-inducing	NULL
ligand	NULL
)	NULL
:	NULL
A	NULL
new	NULL
receptor	NULL
protecting	NULL
lymphocytes	NULL
from	NULL
the	NULL
death	NULL
ligand	NULL
TRAIL	NULL
.	NULL

J	NULL
Immunol	NULL
160:3	NULL
,	NULL
1998	NULL
46	NULL
.	NULL

Degli-Esposti	NULL
MA	NULL
,	NULL
Dougall	NULL
WC	NULL
,	NULL
Smolak	NULL
PJ	NULL
,	NULL
Waugh	NULL
JY	NULL
,	NULL
Smith	NULL
CA	NULL
,	NULL
Goodwin	NULL
RG	NULL
:	NULL
The	NULL
novel	NULL
receptor	NULL
TRAIL-R4	NULL
induces	NULL
NF-	NULL
<	NULL
B	NULL
and	NULL
protects	NULL
against	NULL
TRAIL-mediated	NULL
apoptosis	NULL
,	NULL
yet	NULL
retains	NULL
an	NULL
incomplete	NULL
death	NULL
domain	NULL
.	NULL

Immunity	NULL
7:813	NULL
,	NULL
1997	NULL
47	NULL
.	NULL

Marsters	NULL
SA	NULL
,	NULL
Sheridan	NULL
JP	NULL
,	NULL
Pitti	NULL
RM	NULL
,	NULL
Huang	NULL
A	NULL
,	NULL
Skubatch	NULL
M	NULL
,	NULL
Baldwin	NULL
D	NULL
,	NULL
Yuan	NULL
J	NULL
,	NULL
Gurney	NULL
A	NULL
,	NULL
Goddard	NULL
AD	NULL
,	NULL
Godowski	NULL
P	NULL
,	NULL
Ashkenazi	NULL
A	NULL
:	NULL
A	NULL
novel	NULL
receptor	NULL
for	NULL
Apo2L/TRAIL	NULL
contains	NULL
a	NULL
truncated	NULL
death	NULL
domain	NULL
.	NULL

Curr	NULL
Biol	NULL
7:1003	NULL
,	NULL
1997	NULL
48	NULL
.	NULL

Smell	NULL
V	NULL
,	NULL
Clodi	NULL
K	NULL
,	NULL
Zhao	NULL
S	NULL
,	NULL
Goodwin	NULL
R	NULL
,	NULL
Thomas	NULL
EK	NULL
,	NULL
Morris	NULL
SW	NULL
,	NULL
Kadin	NULL
ME	NULL
,	NULL
Cabanillas	NULL
F	NULL
,	NULL
Andreeff	NULL
M	NULL
,	NULL
Younes	NULL
A	NULL
:	NULL
Activity	NULL
of	NULL
TNF-related	NULL
apoptosis-inducing	NULL
ligand	NULL
(	NULL
TRAIL	NULL
)	NULL
in	NULL
haematological	NULL
malignan-cies	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
99:618	NULL
,	NULL
1997	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
blO	NULL
0d	NULL
1998	NULL
91	NULL
:	NULL
4624-4631	NULL
Inhibition	NULL
of	NULL
Nuclear	NULL
Factor	NULL
xB	NULL
Activation	NULL
Attenuates	NULL
Apoptosis	NULL
Resistance	NULL
in	NULL
Lymphoid	NULL
Cells	NULL
4	NULL
_	NULL
5	NULL
,	NULL
'	NULL
_	NULL
>	NULL
,	NULL
#	NULL
04	NULL
;	NULL
©1004	NULL
@	NULL
207	NULL
I.	NULL
Jeremias	NULL
,	NULL
C.	NULL
Kupatt	NULL
,	NULL
B.	NULL
Baumann	NULL
,	NULL
|	NULL
.	NULL

Herr	NULL
,	NULL
T.	NULL
Wirth	NULL
and	NULL
K.M	NULL
.	NULL

Debatin	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/91/12/4624.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Immunobiology	NULL
and	NULL
Immunotherapy	NULL
(	NULL
5674	NULL
articles	NULL
)	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

